The event brought together an international delegation of researchers with interests in medicinal chemistry and interfacing disciplines. In addition, a pre-conference workshop provided an opportunity for younger researchers to develop their theoretical knowledge in quantitative pharmacology. Abstracts of presentations by the 14 invited speakers and 6 young researchers, in addition to 41 posters, are included in this report.
Aim and Scope of the Meeting
The GP2A (Groupement des Pharmacochimistes de l Arc Atlantique/Group of Medicinal Chemists in the Atlantic Arc) network is made up of researchers in the field of medicinal chemistry working in universities and research institutes across Europe. It was founded in 1992 with the aim of bringing together researchers to exchange ideas and expertise and facilitate a friendly collaborative networking environment. Historically, it has included members from France, Spain, Portugal, Ireland and the United Kingdom (the "Atlantic Arc"). More recently, it has expanded both geographically and in terms of research fields, now including researchers from areas that range from physical and pharmaceutical chemistry to molecular pharmacology.
The annual GP2A conference host city alternates between France and another country and brings together established scientists and those earlier in their career. In addition, the network facilitates short visits between laboratories. A consistent theme of the annual conference is to provide young researchers an opportunity to present their work to an international audience through either poster presentation or by sharing the stage with invited speakers.
The 2019 conference was held at the East Midlands Conference Centre and hosted by the Division of Biomolecular Science and Medicinal Chemistry (BSMC), within the School of Pharmacy at the University of Nottingham (UoN). Ahead of the workshop, young researchers were invited to attend a pre-conference workshop, led by Prof. Steven J. Charlton (UoN/Excellerate Bioscience) and Dr Elizabeth Rosethorne (UoN). The meeting opened and closed with two internationally recognised plenary speakers, Prof. Peter Gmeiner (Friedrich-Alexander University, Erlangen-Nürnberg, Germany) and Prof. Rob Leurs (Vrije-Universiteit, Amsterdam, The Netherlands). In addition, there were a further 12 invited speaker talks, 6 young researcher talks and 41 posters, selected from over 50 submitted abstracts.
The opioid epidemic has rapidly evolved into a medical crisis, with recent figures suggesting 11.5 million people in the United States had misused prescription opioids and >17,000 deaths had been caused by commonly prescribed opioids in 2016 alone. A long sought-after but elusive solution has been the development of a strong but safe opioid analgesic-The Holy Grail of opioid research. Our approach has been to develop analgesics, such as BU08028 (Ding, H., et al. PNAS, 2016, 113, E5511-E5518), with partial agonist activity at both mu and nociceptin/orphanin FQ peptide receptors, as evidence suggests a synergistic interaction between these receptors for analgesia. BU08028 proved to be a potent, long-acting analgesic in primates and did not cause respiratory dependence or reduce respiration. Having defined a pharmacophore for mixed mu and nociception receptor binding, we were able to design a further series of mixed ligands based on the oxymorphone scaffold. BU10038 was identified from within this series as having an almost identical receptor profile to BU08028 and has now been evaluated in a battery of assays to define its analgesic and side effect profile (Kiguchi, N., et al. Brit. J. Anaesthesia, 2019, 122, e146-e156). Following systemic administration in non-human primates, BU10038 (0.001-0.01 mg kg −1 ) dose-dependently produced long-lasting antinociceptive and antihypersensitive effects. Unlike the standard analgesic oxycodone, BU10038 lacked reinforcing effects (i.e., had little or no abuse liability), and compromised the physiological functions of primates including respiration, cardiovascular activities and body temperature at antinociceptive doses and at a 10-30-fold higher dose (0.01-0.1 mg kg −1 ). Unlike morphine, BU10038 did not cause the development of physical dependence and tolerance after repeated and chronic administration. This work strongly supports the development Funding from the National Institute on Drug Abuse and Orexigen Therapeutics.
Design of Matrix Metalloproteinase Inhibitors for Inflammatory Bowel Disease (KL6)

Maria Pigott, Jun Wang, Shane O′Sullivan, Carlos Medina and John F Gilmer
School of Pharmacy and Pharmaceutical Sciences, Trinity College Dublin, D2, Ireland; e-mail: gilmerjf@tcd.ie Matrix metalloproteinases (MMPs) is an umbrella term for a large family of widely distributed enzymes that influence diverse biochemical processes relevant to normal physiology and to disease. MMPs are interesting drug targets but they are challenging because of their distribution, range of effects and similarity. The so-called gelatinase B enzyme, also known as MMP-9, is a key player in the progression of inflammatory bowel disease (IBD) and a marker of inflammation and disease progression (O′Sullivan, S., et al. Mediat. Inflamm. 2015, 2015, [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] . This talk will describe the biology of MMP-9 in IBD and provide an overview of our attempts to design inhibitors that selectively affect its function. These efforts relate to three broad strategies: (i) attempts at increasing MMP-9 selectivity in the pyrimidinetrione class through conventional medicinal chemistry approaches (Wang, J., et al. Bioorg. Med. Chem. 2011, 19, 16, 4985-4999) ; (ii) hybrid tactics using nitric oxide mimetic functionality to influence MMP transcription (O′Sullivan, S., et al. Br. J. Pharmacol. 2017, 174, 512-524; Wang. J.; O′Sullivan, S., et al. J. Med. Chem. 2012, 55, 2154-2162); (iii) quasi pharmaceutical strategies to confine broadly unselective pyrimidinetrione inhibitors to disease tissue through manipulation of chemical properties. The outcomes of these attempts and lessons learned will be related through data from in vitro/in vivo models of ulcerative colitis.
Computational Medicinal Chemistry Approaches for GPCR Structure-Based Drug Discovery (KL7)
Chris De Graaf
Sosei Heptares; e-mail: Chris.DeGraaf@heptares.com Novel crystal structures of GPCR-ligand complexes solved at Sosei Heptares and elsewhere continue to reveal a diversity of potential ligand binding sites. Emerging sets of GPCR crystal structures of multiple diverse ligands bound to closely related receptors furthermore finally enable a protein structure-based view of how different ligands bind this major drug target class.
This presentation will address several important repercussions and learnings from the analysis of GPCR structures for ligand design that should be transferable and relevant for many targets, both GPCRs and enzymes, including:
• Caveats in using pharmacophore-based similarity principles for modeling receptor ligand complexes different ligand chemotypes.
•
The important roles of lipophilic hot spots and water networks as drivers of GPCR druggability, ligand binding and selectivity.
Funding from the National Institute on Drug Abuse and Orexigen Therapeutics. Matrix metalloproteinases (MMPs) is an umbrella term for a large family of widely distributed enzymes that influence diverse biochemical processes relevant to normal physiology and to disease. MMPs are interesting drug targets but they are challenging because of their distribution, range of effects and similarity. The so-called gelatinase B enzyme, also known as MMP-9, is a key player in the progression of inflammatory bowel disease (IBD) and a marker of inflammation and disease progression (O Sullivan, S., et al. Mediat. Inflamm. 2015, 2015, 1-18). This talk will describe the biology of MMP-9 in IBD and provide an overview of our attempts to design inhibitors that selectively affect its function. These efforts relate to three broad strategies: (i) attempts at increasing MMP-9 selectivity in the pyrimidinetrione class through conventional medicinal chemistry approaches (Wang, J., et al. Bioorg. Med. Chem. 2011, 19, 16, 4985-4999); (ii) hybrid tactics using nitric oxide mimetic functionality to influence MMP transcription (O Sullivan, S., et al. Br. J. Pharmacol. 2017, 174, 512-524; Wang. J.; O Sullivan, S., et al. J. Med. Chem. 2012, 55, 2154-2162); (iii) quasi pharmaceutical strategies to confine broadly unselective pyrimidinetrione inhibitors to disease tissue through manipulation of chemical properties. The outcomes of these attempts and lessons learned will be related through data from in vitro/in vivo models of ulcerative colitis.
Computational Medicinal Chemistry Approaches for GPCR Structure-Based Drug Discovery (KL7)
Chris De Graaf Sosei Heptares; Chris.DeGraaf@heptares.com Novel crystal structures of GPCR-ligand complexes solved at Sosei Heptares and elsewhere continue to reveal a diversity of potential ligand binding sites. Emerging sets of GPCR crystal structures of multiple diverse ligands bound to closely related receptors furthermore finally enable a protein structure-based view of how different ligands bind this major drug target class.
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•
Binding mode diversity of (chemically similar) ligands across the structural GPCRome.
This presentation will show how the breakthroughs in GPCR structural biology can be complemented by computational and experimental studies for a more accurate description and prediction of molecular and structural determinants of ligand-receptor binding affinity, kinetics, potency and selectivity. Integrated cheminformatics workflows will be described that combine structural, pharmacological and chemical data to explore receptor-ligand interaction space and steer structure-based virtual ligand screening. Novel cheminformatics-driven molecule design approaches will be discussed, combining retrosynthetic analysis, library enumeration approaches (e.g., matched molecular pairs analysis) and recurrent neural network-driven molecule generation.
We will discuss how the accumulated GPCR structural chemogenomics data can be used to construct customized structure-based medicinal chemistry toolboxes for hit optimization and library design. Orthogonal physics-based (Molecular Dynamics, e.g., Free Energy Perturbation FEP+, WaterMap from Schrödinger) and empirical (e.g., GRID and WaterFLAP from Molecular Discovery) structure-based drug design methods will be presented to target lipophilic hotspots, water networks and cryptic ligand binding pockets for a variety of GPCR subfamilies.
Phenotypic Activity Driven Target Identification and Discovery of Drug Candidates (KL8)
Paul Wyatt Drug Discovery Unit, Wellcome Centre for Anti-Infectives Research, University of Dundee, School of Life Sciences, Dundee DD1 5EH, UK; P.G.Wyatt@dundee.ac.uk There are considerable opportunities for drug discovery centres based in universities to generate benefit to patients, provided they do not compete with or merely replicate BioPharma. The centres have to develop activities complementary to, or in partnership with the BioPharma industry. These include partially de-risking novel drug discovery targets, or tackling neglected and orphan diseases. The Drug Discovery Unit seeks to achieve this by combining a globally rare university-based, fully integrated drug discovery group capable of delivering new drug candidates with a world-class life sciences research environment and multiple partners to develop the drug discovery approaches to major global diseases.
The talk describes how we are delivering much needed clinical candidates, for example, malaria and visceral leishmaniasis (two) by taking a phenotypic approach to hit identification and optimisation, using mode of action studies to identify novel drug targets and to manage a portfolio of phenotypically derived projects. Humans have employed resins for esthetic, ceremonial or therapeutic uses for millennia (Klemens, F., Dieter, G. "Resins, Natural". Ullmann s Encyclopedia of Industrial Chemistry, 2000). Gum rosin, in particular, has an annual worldwide production of more than 1 million tons and is used as an ingredient for inks, varnishes, adhesives, cosmetics, medicines and chewing gums. The ecological role of resins is protective, that is, when trees are cut, the volatiles in the resin evaporate leaving Pharmaceuticals 2019, 12, 179 9 of 47 the solid portion that contains "resin acids", which shelter them from external stress and invaders, promoting healing.
Our research has revealed that these "resin acids", belonging to the class of abietane-type diterpenoids, have antimicrobial and anti-biofilm activity towards gram-positive bacteria and can be exploited for human use (Fallarero, A., et al. Int. J. Mol. Sci. 2013, 14, 12054-12072). Through chemistry, we have created a library of over 50 new chemically pure "resin acids" derivatives, which includes, to the best of our knowledge, the most potent agents reported within their class so far (Manner, S., et al. Eur. J. Med. Chem. 2015, 102, 68-79; Moreira, V.M., et al. WO 2016/051013 A1, 7th April 2016). It is noteworthy that this effect is accompanied by a good tolerability profile and low potential for spreading resistance. Moreover, combination of these compounds with nanocellulose, an advanced biopolymer with excellent mechanical properties and biocompatibility, resulted in innovative and cost-effective functional surfaces, bearing a broad spectrum of action against bacteria, high biocompatibility and no cross-resistance with drug-resistant strains (Hassan, G., et al. ACS Sustainable Chem. Eng. 2019, 7, [5002] [5003] [5004] [5005] [5006] [5007] [5008] [5009] . This presentation will detail the outcomes of our work with this class of compounds and further illustrate how natural products and their derivatives foster innovation in antimicrobial research.
Acknowledgements: The Finnish Funding Agency for Technology and Innovation (project 1297/31/2016).
Glycoconjugates Disrupting Bacterial and Fungal Adhesion Mechanisms (KL10)
Sébastien G. Gouin University of Nantes, CEISAM, Chimie Et Interdisciplinarité, Synthèse, Analyse, Modélisation, UMR CNRS 6230, UFR des Sciences et des Techniques, 2, rue de la Houssinière, BP 92208, 44322 NANTES Cedex 3, France; sebastien.gouin@univ-nantes.fr Increasing resistance to antibiotics or antifungals is a serious health problem, which is worsening with the constant identification of strains resilient to commonly available chemotherapeutic agents. Among the therapeutic alternatives developed at the academic level, the anti-adhesive strategy has seen a growing interest in the last 25 years (Cecioni, S., et al. Chem. Rev. 2015, 115, 525-561). The concept is to disrupt the lectin-mediated adhesion of the pathogen to eukaryotic cells. This therapeutic approach should be less prone to the development of resistances and selection pressures, as the pathogens are not killed during the decolonisation process.
Our group is interested in developping antagonists of carbohydrate-binding and processing proteins (adhesins and glycosidases) to disrupt the attachment of pathogenic bacteria and fungi to host cells. We will discuss the design of mono-and multivalent glycoconjugates and their in vitro and in vivo antiadhesif potential. A specific focus will be made on antagonists of adhesins ( Figure 1 
Drug-Like Properties and Ligand Efficiency-Guided Optimisation (KL11)
Paul Leeson
Paul Leeson Consulting Ltd. and School of Pharmacy, University of Nottingham, UK; leesonpd@gmail.com It has been acknowledged that significant attrition and delay in clinical drug development pipelines has been caused by poor compound properties such as inadequate pharmacokinetics and poor solubility. Generic compound quality guidelines, such as the rule of five, may not always be helpful because differing drug binding sites on biological targets can strongly influence the allowable physicochemical property ranges of their ligands. The application of ligand efficiency measures, which quantify in vitro activities per unit of a physical property such as size or lipophilicity, provides an improved perspective of compound quality over physicochemical properties alone. Thus, candidate drugs and approved drugs are frequently amongst the most ligand efficient for their specific target, on the basis of measures using both size (ligand efficiency, LE) and lipophilicity (ligand lipophilic efficiency, LLE). This is seen even with drugs having extreme physicochemical properties, such as those breaking the rule of five, for example, the new raft of drugs for treatment of the hepatitis C virus. The desirable optimisation destination in the property efficiency space of a novel target can be anticipated once enough screening data are available, usually in the hit-to-lead phase. In conjunction with the application of multiparameter ADMET optimisation, the approach can help to refine drug design options, prioritise synthesis and reduce the numbers of compounds made (Young, R.J., et al. J. Med. Chem. 2018, 61, 6421-6467).
Cedex 3, France; e-mail: sebastien.gouin@univ-nantes.fr Increasing resistance to antibiotics or antifungals is a serious health problem, which is worsening with the constant identification of strains resilient to commonly available chemotherapeutic agents. Among the therapeutic alternatives developed at the academic level, the anti-adhesive strategy has seen a growing interest in the last 25 years (Cecioni, S., et al. Chem. Rev. 2015, 115, 525-561) . The concept is to disrupt the lectin-mediated adhesion of the pathogen to eukaryotic cells. This therapeutic approach should be less prone to the development of resistances and selection pressures, as the pathogens are not killed during the decolonisation process.
Our group is interested in developping antagonists of carbohydrate-binding and processing proteins (adhesins and glycosidases) to disrupt the attachment of pathogenic bacteria and fungi to host cells. We will discuss the design of mono-and multivalent glycoconjugates and their in vitro and in vivo antiadhesif potential. A specific focus will be made on antagonists of adhesins ( Figure 1 Figure 1 . Illustration of the antiadhesive concept. Oral administration of Escherichia coli antiadhesives in Crohn s disease mouse model was shown to lower the bacterial load in the gut and to reduce the inflammatory syndromes. AIEC: adherent-invasive E. coli. In recent years, considerable attention has been paid on melatonergic (MT) receptor agonists given their application for treating insomnia and depression. We synthetized novel hexahydroindenopyridines (HHIP), which were able to bind MT1 and/or MT2 receptors. These HHIP emerged as promising leads for the development of new melatoninergic agents (Parraga, J., et al. Eur. J. Med. Chem. 2014, 30, 700-709).
Drug-Like Properties and Ligand Efficiency-Guided Optimisation (KL11)
Natural Products and Analogues as Potential Therapeutic Agents (KL12)
This work was funded by grants SAF2017-89714-R, SAF2014-57845R, CP15/00150 and PI18/01450 from Ministerio de Ciencia, Innovación, Instituto de Salud Carlos III and co-funded by European Union (ERDF/ ESF) "Investing in your future". In this communication, we report the results from a medicinal chemistry programme focused on a pyrroloquinolone (PQ) series targeting the Plasmodium falciparum mETC (mitochondrial electron transport chain). This previously unknown series 1 was tested against blood-and liver-stage malaria parasites and our hit compound revealed excellent dual-stage inhibitory activity. The plausible structure-activity relationships and the inhibition of mETC components (cytochrome bc 1 , dihydroorotate dehydrogenase) will be discussed in this communication. In addition, our hit compound interfered with calcium homeostasis in transgenic malaria parasites. The interactions between the lead compounds and target were confirmed by docking. Our hit compound also revealed a good selectivity index, in vivo efficacy and favourable pharmacokinetic properties ( Figure 3) . This work was supported by Fundação para a Ciência e Tecnologia (FCT), FEDER and PT2020 through projects UID/DTP/04138/2013 and UID/QUI/00062/2013. We also thank FCT for the fellowships SFRH/BPD/108807/2015 (V.L.M.S.) and SFRH/BD/103412/2014 (G.S.). This work was supported by Fundação para a Ciência e Tecnologia (FCT), FEDER and PT2020 through projects UID/DTP/04138/2013 and UID/QUI/00062/2013. We also thank FCT for the fellowships SFRH/BPD/108807/2015 (V.L.M.S.) and SFRH/BD/103412/2014 (G.S.).
Young Researcher Communications
Molecular Docking, Semisynthesis and Biological Evaluation of Garcinoic Acid Amides as 5-Lipoxygenase Inhibitors (YRC02)
Prostaglandins and leukotriens (LTs), produced from arachidonic acid by cyclo-oxygenase and 5-lipoxygenase (5-LOX) pathways, respectively, are key mediators in inflammation (Funk, C. D. Science 2001, 294, 1871-1875). Our recent results showed an anti-inflammatory activity of ω-oxidized tocotrienols by inhibiting 5-LOX (Pein, H., et al. Nat. Commun. 2018, 9, 3834) . Amongst these compounds, δ-garcinoic acid (δ-GA) was the most active one. It inhibited LTs formation in 5-LOX and polymorphonuclear leukocyte assays with IC50 at 0.04 ± 0.02 µM and 0.35 ± 0.08 µM, respectively. Molecular docking with an in-house dataset was performed and identified new allosteric binding site for these compounds. Prostaglandins and leukotriens (LTs), produced from arachidonic acid by cyclo-oxygenase and 5-lipoxygenase (5-LOX) pathways, respectively, are key mediators in inflammation (Funk, C. D. Science 2001, 294, 1871-1875). Our recent results showed an anti-inflammatory activity of ω-oxidized tocotrienols by inhibiting 5-LOX (Pein, H., et al. Nat. Commun. 2018, 9, 3834). Amongst these compounds, δ-garcinoic acid (δ-GA) was the most active one. It inhibited LTs formation in 5-LOX and polymorphonuclear leukocyte assays with IC 50 at 0.04 ± 0.02 µM and 0.35 ± 0.08 µM, respectively. Molecular docking with an in-house dataset was performed and identified new allosteric binding site for these compounds.
In order to further understand the mode of action and to improve the 5-LOX inhibitory activity of δ-GA or its pharmacological profile, the rational design of a series of amides followed by their semisynthesis was carried out. Here, we present a dataset of novel δ-GA-based anti-inflammatory agents with promising in vitro and in cellulo anti-inflammatory activity. Docking pose of a GA amide into an allosteric binding site of 5-lipoxygenase (5-LOX).
In order to further understand the mode of action and to improve the 5-LOX inhibitory activity of δ-GA or its pharmacological profile, the rational design of a series of amides followed by their semisynthesis was carried out. Here, we present a dataset of novel δ-GA-based anti-inflammatory agents with promising in vitro and in cellulo anti-inflammatory activity. In a world where life expectancy is increasing, Alzheimer disease (AD) is the main cause of dementia, and affects approximatively 17% of people who are older than 75 years in France. This is a progressive neurodegenerative disorder characterized by memory loss and cognitive decline. Despite the fact that the physiopathology of AD is not entirely known at the current time, some molecular causes were found such as the ß-amyloid peptides aggregation, tau-dependent neurofibrillary tangles, as well as oxidative stress and neuroinflammation. Currently, treatments available for patients are mainly acetylcholine esterase (AChE) inhibitors, which only have symptomatic benefits and do not cure AD. Thus, there is still a strong medical need in the AD population.
Polypharmacological Compounds in Alzheimer′s
In this context, the concept of multi-target directed ligands (MTDLs) was applied to design a drug with several therapeutic targets. The envisaged MTDL (targeted structure-Figure 4) should be able to limit the development of ß-amyloid plaques obtained by the aggregation of ß-amyloid peptides (Aß). Indeed, our compounds are designed to promote the cleavage of amyloid protein precursor (APP) by α -secretase activation in order to produce a neuroprotective and soluble peptide sAPPα. This is the role of the 5HT4R agonists, which are already studied in the CERMN (Centre To that end, different compounds will be designed and synthesized, with both the expertise of CERMN and Prof. Maria-Laura Bolognesi, in order to evaluate their in vitro/in vivo properties regarding their agonist
In a world where life expectancy is increasing, Alzheimer disease (AD) is the main cause of dementia, and affects approximatively 17% of people who are older than 75 years in France. This is a progressive neurodegenerative disorder characterized by memory loss and cognitive decline. Despite the fact that the physiopathology of AD is not entirely known at the current time, some molecular causes were found such as the ß-amyloid peptides aggregation, tau-dependent neurofibrillary tangles, as well as oxidative stress and neuroinflammation. Currently, treatments available for patients are mainly acetylcholine esterase (AChE) inhibitors, which only have symptomatic benefits and do not cure AD. Thus, there is still a strong medical need in the AD population.
In this context, the concept of multi-target directed ligands (MTDLs) was applied to design a drug with several therapeutic targets. The envisaged MTDL (targeted structure-Figure 4) should be able to limit the development of ß-amyloid plaques obtained by the aggregation of ß-amyloid peptides (Aß). Indeed, our compounds are designed to promote the cleavage of amyloid protein precursor (APP) by α -secretase activation in order to produce a neuroprotective and soluble peptide sAPPα. This is the role of the 5HT4R agonists, which are already studied in the CERMN (Centre d'Etudes et de Recherche sur le Médicament de Normandie) in other MTDL projects and led to the discovery of donecopride (blue part- Figure To that end, different compounds will be designed and synthesized, with both the expertise of CERMN and Prof. Maria-Laura Bolognesi, in order to evaluate their in vitro/in vivo properties regarding their agonist activity on 5-HT 4 R and antioxidant properties. The development and promising in vitro/in cellulo results of the chloroaniline s moiety line will be described in this presentation. The reactivity of pazopanib and sunitinib aldehyde RM toward different hepatic (human liver microsomes (HLM), recombinant CYP3A4) and plasma (albumin) proteins was investigated by LC-MS/MS to better understand how these RM could be involved in liver toxicity and DDI. Because of the presence of a free amino group on its side chain, lysine could be a good target for reactive electrophiles. Reactions between aldehydes and amines affording imine derivatives are known to be reversible in aqueous media. Thus, adduct formation with these different proteins was examined after reductive amination of imine derivatives by NaBH 3 CN in vitro and after proteolytic digestion. Preliminary studies were carried out with free lysine and aldehyde RM generated beforehand by biomimetic oxidation reactions catalysed by metalloporphyrins. Lysine adduct formation was then studied with aldehyde RM generated in situ in HLM and recombinant CYP3A4 incubations. Aldehyde-lysine adducts on both CYP3A4 and plasma proteins were detected for the first time by LC-MS for pazopanib and sunitinib and characterized by the related [M+H] + ions and MS/MS fragmentation patterns. In addition, the formation of aldehyde RM in vivo was investigated in plasma samples from patients treated, separately, with pazopanib or sunitinib. These aldehyde RM have been unambiguously detected in patient plasma samples during drug monitoring. Thus, it could be hypothesized that the coupling of pazopanib or sunitinib aldehydes with lysine residues of CYP3A4 and hepatic proteins may be involved both in hepatotoxicity and DDI. Despite the best efforts and investment from the last decade, malaria s death toll still amounts to nearly half a million people a year, and no reduction of the diagnosed cases was observed in the last two years. Furthermore, parasite resistance is already reported for every drug class in clinical use. These makes this protozoan infection a major public health concern mainly in the tropical regions of the globe (WHO. World Malaria Report. 2018). To overcome these hurdles, it is critical to advance new drugs with different mechanisms of action.
With that in mind, we have already disclosed Torin2, known as an ATP-competitive mTOR kinase inhibitor (Liu, Q., et al. J. Med. Chem. 2011, 54, 1473), as a portent antimalarial lead compound that possesses in vivo activity in mice against the blood and liver stages. Compound activity was shown to be independent of the host mTOR pathway and does not involve the mechanisms already knows for drugs in clinic (Hanson, K. K., et al. Proc. Natl. Acad. Sci. U.S.A. 2013, 110, E2838).
Here, we report the development of Torin2 photoaffinity-based probes to deconvolute the molecular target(s) of this compound in the parasite. This was achieved through the modification of the core scaffold with a photocrosslinker and a handle suitable for 'click chemistry'. Furthermore, we disclose the application of these chemical tools in a mass spectrometry-based proteome profiling of P. falciparum lysates and live cultures of the disease blood stage (Scheme 1). The results thus obtained are fundamental optimization of Torin2-based compounds as a new alternative to current antimalarials, a key breakthrough to address the existing therapeutic gap. Despite the best efforts and investment from the last decade, malaria′s death toll still amounts to nearly half a million people a year, and no reduction of the diagnosed cases was observed in the last two years. Furthermore, parasite resistance is already reported for every drug class in clinical use. These makes this protozoan infection a major public health concern mainly in the tropical regions of the globe (WHO. World Malaria Report. 2018). To overcome these hurdles, it is critical to advance new drugs with different mechanisms of action.
Here, we report the development of Torin2 photoaffinity-based probes to deconvolute the molecular target(s) of this compound in the parasite. This was achieved through the modification of the core scaffold with a photocrosslinker and a handle suitable for 'click chemistry'. Furthermore, we disclose the application of these chemical tools in a mass spectrometry-based proteome profiling of P. falciparum lysates and live cultures of the disease blood stage (Scheme 1). The results thus obtained are fundamental optimization of Torin2-based compounds as a new alternative to current antimalarials, a key breakthrough to address the existing therapeutic gap. Scheme 1. (A) Torin2 hit compound; (B) structure of the photo-affinity labelling probe I, derived from Torin2 by the introduction of a diazirine photoreactive moiety (in red) and a terminal alkyne handle for CuAAC chemistry (in green) and (C) schematic overview of the methodology applied for Plasmodium falciparum cell-based proteome profiling. In red: Diazirine before (star) and after (circle) irradiation. In pink: TAMRA and/or Biotin azide capture reagents.
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FCT-Portugal, (PTDC/QEQ-MED/7097/2014)(PD/BD/128260/2016)(IF/01034/2014). One such approach gaining ever more interest is the attenuation of virulence through the silencing of quorum sensing, a form of community-based cell-to-cell communication. The opportunistic pathogen Pseudomonas aeruginosa is the greatest contributor to morbidity in cystic fibrosis patients, and causes chronic and persistent infections in immunocompromised patients, particularly in a hospital environment.
The Development of a 6-Chloro-3-(Thiazole)Methyl-Quinazolin-4(3H)-One Series as
Previous studies have evidenced the attenuation of virulence through the suppression of its alkylquinolone-based quorum sensing system, Pseudomonas quinolone system (pqs) (Ilangovan, A., et al. PLoS Pathog. 2013, 9, e1003508). Herein, we report the synthesis and biological evaluation of a novel series of 6-chloro-3-(thiazole)methyl-quinazolin-4(3H)-one compounds (Figure 1 ) through the determination of their biological activity using both P. aeruginosa PAO1-L mCTX:P pqsA -lux and PA14 mCTX:P pqsA -lux bioreporter strains. We report structural evaluation of their binding mode through generating protein-ligand crystal structures of this class of novel inhibitors in the PqsR ligand binding domain. The structure-activity relationship (SAR) study verified the binding mode to be comparable with that of the natural agonists HHQ and PQS, whilst providing lead pqs inhibitors with IC 50 s in the 100 nM range. As the rise in antimicrobial resistance continues to reduce treatment options for a variety of pathogens at an alarming rate, the need for alternate antimicrobial agents grows ever more urgent. One such approach gaining ever more interest is the attenuation of virulence through the silencing of quorum sensing, a form of community-based cell-to-cell communication. The opportunistic pathogen Pseudomonas aeruginosa is the greatest contributor to morbidity in cystic fibrosis patients, and causes chronic and persistent infections in immunocompromised patients, particularly in a hospital environment.
Previous studies have evidenced the attenuation of virulence through the suppression of its alkylquinolone-based quorum sensing system, Pseudomonas quinolone system (pqs) (Ilangovan, A., et al. PLoS Pathog. 2013, 9, e1003508). Herein, we report the synthesis and biological evaluation of a novel series of 6-chloro-3-(thiazole)methyl-quinazolin-4(3H)-one compounds (Figure 1 ) through the determination of their biological activity using both P. aeruginosa PAO1-L mCTX:PpqsA-lux and PA14 mCTX:PpqsA-lux bioreporter strains. We report structural evaluation of their binding mode through generating protein-ligand crystal structures of this class of novel inhibitors in the PqsR ligand binding domain. The structure-activity relationship (SAR) study verified the binding mode to be comparable with that of the natural agonists HHQ and PQS, whilst providing lead pqs inhibitors with IC50s in the 100 nM range.
(left) The structures of cognate ligands HHQ and Pseudomonas quinolone system (PQS); (right) the 6-chloro-3-ithiazole)methyl-quinazolin-4(3H)-one scaffold of PqsR inhibitors detailed herein.
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Design and Synthesis of New Integrated Stress Response Inhibitor (ISRIB) Analogues Targeting eIF2B as Potential Candidates for Enhancing Protein Synthesis Rate (P01)
Akeel Abo Alard 1,2 , David Ron 3 , Ana Crespillo-Cresado 3 , Alisa Zyryanova 3 , Christophe Fromont 1 ,Dave Barrett 1 , Catherine Oteri 1 , Pavel Gershkovich 1 , Jong Bong Lee 1 , Barrie Kellam 1 and Peter Fischer 1
Neurodegenerative diseases represent the major cause of dementia, which is predominantly a disease of the elderly, and is characterised by a decline in cognitive functions and memory. All these diseases share a similar aetiology, that is, the production and accumulation of misfolded proteins in the brain. This results in increasing the activity of the protein kinase RNA-like endoplasmic reticulum kinase PERK/eIF2α-P pathway of the unfolded protein response (UPR), which in turn leads to the inhibition of protein synthesis. According to a recent study the small-molecule integrated stress response inhibitor (ISRIB) reduces the level of eIF2α-P by activating eukaryotic initiation factor 2B (eIF2B), a guanine nucleotide exchange factor (GEF) for eIF2α, resulting in enhancement of protein synthesis based on in vivo study in the cell-based luciferase reporter assay (Sidrauski, C., et al. Elife. Figure 5 ). Synthesis of truncated ISRIB analogues revealed that even subtle modifications have an obvious impact on activity. Central core ring was also explored, and it was found that its replacement with 1,4-diaminopiperazine and 1,4-diaminopiperdine retained high activity. Furthermore, to assist in observe ISRIB s interaction with eIF2B, we designed and synthesised fluorescently label derivative, considering the most active compound, with a modified aryl ether portion that was then used to elaborate the fluorescently label compound. The derivatized compound contained a flexible linker terminating in a 5/6-carboxyfluorescein moiety (Zyryanova, A. F., et al. Figure 5 ). Synthesis of truncated ISRIB analogues revealed that even subtle modifications have an obvious impact on activity. Central core ring was also explored, and it was found that its replacement with 1,4-diaminopiperazine and 1,4-diaminopiperdine retained high activity. Furthermore, to assist in observe ISRIB′s interaction with eIF2B, we designed and synthesised fluorescently label derivative, considering the most active compound, with a modified aryl ether portion that was then used to elaborate the fluorescently label compound. The derivatized compound contained a flexible linker terminating in a 5/6-carboxyfluorescein moiety ( In the present work, the synthesis of 3-fluoro and 3,3-difluoro substituted β-lactams was developed easily by a convenient microwave assisted Reformatsky reaction using ethyl bromofluoroacetate and ethyl bromodifluoroacetate, respectively (Scheme 2). To the best to our knowledge, this is the first report of this new synthetic approach for 3-fluoro and 3,3-difluoro β-lactams as CA-4 analogues. The reaction was successful with short reaction time compared to the conventional Staudinger reaction, with moderate yield and few steps required, and it was demonstrated to be a convenient and facile method for the preparation of a variety of 3-fluoro and 3,3-difluoro β-lactams. The 3-fluoro β-lactams In the present work, the synthesis of 3-fluoro and 3,3-difluoro substituted β-lactams was developed easily by a convenient microwave assisted Reformatsky reaction using ethyl bromofluoroacetate and ethyl bromodifluoroacetate, respectively (Scheme 2). To the best to our knowledge, this is the first report of this new synthetic approach for 3-fluoro and 3,3-difluoro β-lactams as CA-4 analogues. The reaction was successful with short reaction time compared to the conventional Staudinger reaction, with moderate yield and few steps required, and it was demonstrated to be a convenient and facile method for the preparation of a variety of 3-fluoro and 3,3-difluoro β-lactams. The 3-fluoro β-lactams (1-8) and 3,3-difluoro β-lactams (9-16) in this series contained the 3,4,5-trimethoxyphenyl ring A, (required for potent activity of CA-4), together with various ring B substituents. The structure of β-lactams 6 and 14 was confirmed by X-ray crystallography. Preliminary cell viability studies demonstrated the antiproliferative effects of these novel compounds, with an IC 50 value of 0.153 µM for 6 in MCF-7 human breast cancer cell line. 
Novel Synthesis of 3-Fluoro and 3,3-Difluoro Substituted β-Lactams: Evaluation as Potential Anticancer Agents (P02)
The Influence of Fluorination on Aliphatic Lipophilicity (P03)
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Fluorination of bioactive compounds is commonly employed in the drug optimisation process, given its potential to modulate a range of properties, and its ability to prevent or slow down undesired processes such as oxidation and/or acid-catalysed degradation. In this context, aliphatic fluorination (as opposed to aromatic fluorination) is receiving increasing interest. Our group is The introduction of fluorine on aliphatic (sp 3 ) carbon often leads to a reduction in lipophilicity, and is the result of a number of effects including hydrophobic surface and dipole introduction, as well as reduction of polarizability. The importance of these opposing effects depends also on a number of factors such as absolute lipophilicity and conformational effects, the latter of which can, in turn, be very different in water and octanol.
We developed a convenient 19 F NMR-based method for the logP-determination of fluorinated compounds, thus not relying on UV-activity, and used this methodology for an extensive study of aliphatic lipophilicity based on an alkanol scaffold.
This presentation will give an overview of these, and other, unpublished findings, and will involve an extensive list of aliphatic fluorination motifs.
Exploring the Impact of Polymer Size on the Biological Activity of PEG-Haloperidol Conjugates (P04)
Az Alddien Natfji, Camilla Pegoraro , Kim Watson, Helen Osborn and Francesca Greco
School of Pharmacy, University of Reading, Whiteknights PO BOX 224 Reading RG6 6AD Berkshire, United Kingdom; e-mail: c.pegoraro@student.reading.ac.uk Haloperidol (HA) is a well-known antagonist of D2 receptors, clinically used as an antipsychotic. Moreover, HA has been shown to be a ligand of different types of receptors (centrally and peripherally) including σ receptors, which have a role in the growth and development of different types of solid tumours (van Waarde, A., et al., Biochim. Biophys. Acta Biomembr. 2015, 1848, 2703-2714). However, HA, as a small molecule, has the ability to permeate across the blood-brain barrier (BBB) and, consequently, produces central nervous system (CNS) (extrapyramidal) side effects, which Scheme 2. Synthesis of 3-fluoro and 3,3-difluoro β-lactams by the microwave assisted Reformatsky reaction. Reagents and conditions: (a) Zn dust, (CH 3 ) 3 SiCl, 40 • C, 2 min, microwave; C 6 H 6 , 100 • C, 30 min, microwave; products obtained as a racemic mixture, one enantiomer represented.
The Influence of Fluorination on Aliphatic Lipophilicity (P03)
Bruno Linclau
School of Chemistry, University of Southampton, Southampton SO171BJ, UK; bruno.linclau@soton.ac.uk Fluorination of bioactive compounds is commonly employed in the drug optimisation process, given its potential to modulate a range of properties, and its ability to prevent or slow down undesired processes such as oxidation and/or acid-catalysed degradation. In this context, aliphatic fluorination (as opposed to aromatic fluorination) is receiving increasing interest. Our group is interested in investigating how fluorination affects molecular conformation ( The introduction of fluorine on aliphatic (sp 3 ) carbon often leads to a reduction in lipophilicity, and is the result of a number of effects including hydrophobic surface and dipole introduction, as well as reduction of polarizability. The importance of these opposing effects depends also on a number of factors such as absolute lipophilicity and conformational effects, the latter of which can, in turn, be very different in water and octanol.
Exploring the Impact of Polymer Size on the Biological Activity of PEG-Haloperidol Conjugates (P04)
Az Alddien Natfji, Camilla Pegoraro, Kim Watson, Helen Osborn and Francesca Greco School of Pharmacy, University of Reading, Whiteknights PO BOX 224 Reading RG6 6AD Berkshire, UK; c.pegoraro@student.reading.ac.uk Haloperidol (HA) is a well-known antagonist of D 2 receptors, clinically used as an antipsychotic. Moreover, HA has been shown to be a ligand of different types of receptors (centrally and peripherally) including σ receptors, which have a role in the growth and development of different types of solid tumours (van Waarde, A., et al., Biochim. Biophys. Acta Biomembr. 2015, 1848, 2703-2714). However, HA, as a small molecule, has the ability to permeate across the blood-brain barrier (BBB) and, consequently, produces central nervous system (CNS) (extrapyramidal) side effects, which limits its peripheral clinical applications. We have previously suggested that conjugating HA to a non-biodegradable polymer through a biologically stable linker could minimise or even prevent its diffusion though the BBB while retaining its biological efficacy ( Figure 6 ). Therefore, conjugation between PEG, a non-biodegradable polymer, and HA through a carbamate linkage (biologically stable) was developed for the first time by our group (Heath, F., et al. Polym. Ch. 2016, 7204-7210). In silico and in vitro studies revealed that the conjugated HA is extremely unlikely to cross the BBB and that it maintains binding activity towards D 2 receptors, but at low level. In the present study, we evaluated the impact of polymer size on the biological activity of PEG-HA on σ receptors in vitro. In addition to this, molecular docking studies, in σ and D 2 receptors, were performed to understand the effect of conjugation on the binding of HA to these receptors.
Pharmaceuticals 2019, 12, x FOR PEER REVIEW 19 of 47 diffusion though the BBB while retaining its biological efficacy ( Figure 6 ). Therefore, conjugation between PEG, a non-biodegradable polymer, and HA through a carbamate linkage (biologically stable) was developed for the first time by our group (Heath, F., et al. Polym. Ch. 2016, 7204-7210). In silico and in vitro studies revealed that the conjugated HA is extremely unlikely to cross the BBB and that it maintains binding activity towards D2 receptors, but at low level. In the present study, we evaluated the impact of polymer size on the biological activity of PEG-HA on σ receptors in vitro. In addition to this, molecular docking studies, in σ and D2 receptors, were performed to understand the effect of conjugation on the binding of HA to these receptors. PEG-HA conjugates, using different sizes of PEG (6000, 2000 Da), were synthetized and characterised. A two-step synthesis was carried out: first, HA was modified to have an amine handle that allows conjugation; second, the HA-amine handle was conjugated to NHS-activated PEG. In vitro cytotoxicity studies, via σ receptors, were performed on MCF-7. The IC50 values of free HA and PEG-HA conjugates were determined using the MTT assay. In parallel, molecular docking studies were conducted. The results revealed that conjugating HA to PEG affected its binding to the receptors. In the case of D2 receptors, the position of PEG-HA inside the pocket was different compared to free HA while retaining the salt bridge interaction with Asp114, which has been indicated to be essential for the biological activity. These findings might justify the reduced biological activity observed for PEG-HA in vitro. Regarding the σ receptors, initial results indicated that conjugating HA to PEG influenced its binding to these receptors. . P. aeruginosa has several QS systems, one of which, the Pseudomonas quinolone system (pqs) uses alkyl-quinolone (AQ)-derived QS molecules. PqsR is the key regulatory protein responsible for the activation of the pqs system upon interaction with the P. aeruginosa ligands (2-heptyl-3-hydroxy-4(1H)-quinolone (PQS) and 2-heptyl-4-hydroxyquinoline (HHQ)) to drive the upregulation of AQ production (feedback activation) and virulence factors biosynthesis (Ilangovan, A., et al. PLoS Pathog. 2013, 9(7), e1003508). It has been shown that the inhibition of the PqsR receptor attenuates bacterial pathogenicity, without affecting bacterial growth PEG-HA conjugates, using different sizes of PEG (6000, 2000 Da), were synthetized and characterised. A two-step synthesis was carried out: first, HA was modified to have an amine handle that allows conjugation; second, the HA-amine handle was conjugated to NHS-activated PEG. In vitro cytotoxicity studies, via σ receptors, were performed on MCF-7. The IC 50 values of free HA and PEG-HA conjugates were determined using the MTT assay. In parallel, molecular docking studies were conducted. The results revealed that conjugating HA to PEG affected its binding to the receptors. In the case of D 2 receptors, the position of PEG-HA inside the pocket was different compared to free HA while retaining the salt bridge interaction with Asp114, which has been indicated to be essential for the biological activity. These findings might justify the reduced biological activity observed for PEG-HA in vitro. Regarding the σ receptors, initial results indicated that conjugating HA to PEG influenced its binding to these receptors.
Design, Synthesis and Evaluation of Novel PqsR Inhibitors as Adjuvant Therapy to Treat Pseudomonas aeruginosa Infections (P05)
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Design, Synthesis and Evaluation of Novel PqsR Inhibitors as Adjuvant Therapy to Treat Pseudomonas aeruginosa Infections (P05)
P. aeruginosa ligands (2-heptyl-3-hydroxy-4(1H)-quinolone (PQS) and 2-heptyl-4-hydroxyquinoline (HHQ)) to drive the upregulation of AQ production (feedback activation) and virulence factors biosynthesis (Ilangovan, A., et al. PLoS Pathog. 2013, 9(7), e1003508). It has been shown that the inhibition of the PqsR receptor attenuates bacterial pathogenicity, without affecting bacterial growth and viability. Our aim was to design, synthesise and evaluate a series of new PqsR inhibitors using a quinazolinone-derived molecule (SEN016, IC 50 3.2 µM) that was found during a high-throughput screening (HTS) (Figure 7 ). Replacement of the quinazolinone ring by benzimidazole (SEN089) enhanced the activity (IC 50 0.067 µM). However, further lead optimisation was required to enhance its biological and physiochemical profile. The co-crystal structure of SEN089 with PqsR LBD was determined and used to guide the lead optimisation strategy. Herein, we report further SAR analysis around modifications (R 1 , R 2 and R 3 ) of SEN089, which resulted in a series of novel PqsR inhibitors with enhanced biological activity and improved physiochemical properties.
Pharmaceuticals 2019, 12, x FOR PEER REVIEW 20 of 48 the Pseudomonas quinolone system (pqs) uses alkyl-quinolone (AQ)-derived QS molecules. PqsR is the key regulatory protein responsible for the activation of the pqs system upon interaction with the P. aeruginosa ligands (2-heptyl-3-hydroxy-4(1H)-quinolone (PQS) and 2-heptyl-4-hydroxyquinoline (HHQ)) to drive the upregulation of AQ production (feedback activation) and virulence factors biosynthesis (Ilangovan, A., et al. PLoS Pathog. 2013, 9(7), e1003508). It has been shown that the inhibition of the PqsR receptor attenuates bacterial pathogenicity, without affecting bacterial growth and viability. Our aim was to design, synthesise and evaluate a series of new PqsR inhibitors using a quinazolinone-derived molecule (SEN016, IC50 3.2 µ M) that was found during a high-throughput screening (HTS) (Figure 7 ). Replacement of the quinazolinone ring by benzimidazole (SEN089) enhanced the activity (IC50 0.067 µ M). However, further lead optimisation was required to enhance its biological and physiochemical profile. The co-crystal structure of SEN089 with PqsR LBD was determined and used to guide the lead optimisation strategy. Herein, we report further SAR analysis around modifications (R1, R2 and R3) of SEN089, which resulted in a series of novel PqsR inhibitors with enhanced biological activity and improved physiochemical properties.
(a) (b) Figure 7 . (a) Improvement in the activity from SEN016 (hit) to SEN089 (lead) and the structureactivity relationship (SAR) study of SEN089 based on the modifications of R1, R2 and R3. (b) The cocrystal structure of SEN089 complexed with PqsR CBD domain. This work describes the conception and synthesis in vitro and in vivo biological evaluation of novel multi-target directed ligands (MTDL) able to both activate 5-HT4 receptors, block 5-HT6 This work describes the conception and synthesis in vitro and in vivo biological evaluation of novel multi-target directed ligands (MTDL) able to both activate 5-HT 4 receptors, block 5-HT 6 receptors and inhibit acetylcholinesterase activity (AChE), in order to exert a synergistic anti-amnesic effect, potentially useful in the treatment of Alzheimer s disease (AD). Indeed, both activation of 5-HT 4 and blockage of 5-HT 6 receptors led to an enhanced acetylcholine release, suggesting that it could lead to efficient restoration of the cholinergic neurotransmission deficit observed in AD. Furthermore, 5-HT 4 receptor agonists are able to promote the non-amyloidogenic cleavage of the amyloid precursor protein (APP) and to favour the production of the neurotrophic protein sAPPα. Finally, we identified a pleiotropic compound, [1-(4-amino-5-chloro-2-methoxyphenyl)-3-(1-(3-methylbenzyl)piperidin-4-yl)propan-1-one fumaric acid salt, which displayed in vivo an anti-amnesic effect in a model of scopolamine-induced deficit of working memory at a dose of 0.3 mg/kg. Inflammation is a hallmark of most neurological disorders and the ability to detect, quantify and monitor the inflammatory response of the central nervous system (CNS) could have large implication for both diagnosis and therapeutic response prediction (V. Wee Yong, Neuroscientist. 2010; 16: 408-20). Among the different diagnostic modalities suitable to detect neuro-inflammation, plasmatic biomarkers can be used, but no reliable and specific plasmatic biomarker of neuro-inflammation has been identified to date. Recently, molecular imaging of neuro-inflammation has been developedthe in vivo detection of a protein, the P-selectin, which is over-expressed at the luminal surface of endothelial cells during neuro-inflammation was performed using micro-sized particles of iron oxide (MPIO). However, this biosensor cannot be used in humans because of its toxicity.
A Novel in Vivo Anti-Amnesic Agent, Specially Designed to Express Both Acetylcholinesterase (AChE) Inhibitory, Serotonergic Subtype 4 Receptor (5-HT4R) Agonist and Serotonergic Subtype 6 Receptor (5-HT6R) Inverse Agonist Activities, with a Potential Interest against Alzheimer′s Disease (P06)
Hyper-polarised xenon-129 (HP-129Xe) has recently emerged as a promising biocompatible contrast agent to improve sensitivity of MRI, successfully used to acquire images of the human pulmonary system (Liburn, D. M. L., et al. J. Magn. Reson. 2013, 7, 173) and brain (Swanson, S. D., et al. Magn. Reson. Med. 1997, 38, 695). However, this gas is not specific of a biological target, and therefore it has to be vectorised using a molecular host to be a valuable biosensor. Among them, cryptophanes showed very good xenon encapsulation properties, leading to a number of in vitro studies using HP-129Xe cryptophane-based biosensors reported in the literature since the 2000s Inflammation is a hallmark of most neurological disorders and the ability to detect, quantify and monitor the inflammatory response of the central nervous system (CNS) could have large implication for both diagnosis and therapeutic response prediction (V. Wee Yong, Neuroscientist. 2010; 16: 408-20). Among the different diagnostic modalities suitable to detect neuro-inflammation, plasmatic biomarkers can be used, but no reliable and specific plasmatic biomarker of neuro-inflammation has been identified to date. Recently, molecular imaging of neuro-inflammation has been developed-the in vivo detection of a protein, the P-selectin, which is over-expressed at the luminal surface of endothelial cells during neuro-inflammation was performed using micro-sized particles of iron oxide (MPIO). However, this biosensor cannot be used in humans because of its toxicity.
Hyper-polarised xenon-129 (HP-129Xe) has recently emerged as a promising biocompatible contrast agent to improve sensitivity of MRI, successfully used to acquire images of the human pulmonary system (Liburn, D. M. L., et al. J. Magn. Reson. 2013, 7, 173) and brain (Swanson, S. D., et al. Magn. Reson. Med. 1997, 38, 695). However, this gas is not specific of a biological target, and therefore it has to be vectorised using a molecular host to be a valuable biosensor. Among them, cryptophanes showed very good xenon encapsulation properties, leading to a number of in vitro studies using HP-129Xe cryptophane-based biosensors reported in the literature since the 2000s (Wang, Y., et al. Acc. Chem. Res. 2016, 49, 2179-2187).
Here, we propose the design and the synthesis of a new biocompatible MRI biosensor composed of a cryptophane core able to encapsulate xenon, and a well-characterized P-selectin antibody able to selectively bind endothelial P-selectin with high affinity. The two parts will be connected with a linker using copper-free click chemistry to afford the desire biosensor ( Figure 8 ). In this presentation, we will focus on the conception and the synthesis of the biosensor. In recent years much effort has been devoted to the design of potent and selective glycosidase inhibitors. However, potential candidates often lack of glycosidase selectivity, and non-specific inhibitions may lead to severe side-effects. Limiting selectivity issues is a challenge unmet with the first generation of inhibitors.
Sialidases are glycosidases involved in many physiological and pathological functions. Many viruses, bacteria and parasites produce this enzyme to cleave sialic acid residues from host cells, unmasking membrane receptors for adhesion and invasion In this work, we developed an alternative approach to the "lock and key concept" to achieve high affinities and selectivities for sialidases (Brissonnet, Y., et al. Chem. Eur. J. 2019, 25 (9), 2358-2365). Multivalent thiosialosides were designed to bind to both the CAT and the CBM of pathogenic sialidases.
Sialidases from Vibrio cholerae, Trypanosoma cruzi and Streptococcus pneumoniae were produced with and without the CBM to determine the importance of dual targeting and the validity of the multivalent concept ( Figure 9 ). In this presentation, we will focus on the conception and the synthesis of the biosensor. In recent years much effort has been devoted to the design of potent and selective glycosidase inhibitors. However, potential candidates often lack of glycosidase selectivity, and non-specific inhibitions may lead to severe side-effects. Limiting selectivity issues is a challenge unmet with the first generation of inhibitors.
Sialidases are glycosidases involved in many physiological and pathological functions. Many viruses, bacteria and parasites produce this enzyme to cleave sialic acid residues from host cells, unmasking membrane receptors for adhesion and invasion These sialidases with CAT and CBM are virulence factors common to many protozoal and pathogenic bacteria, and are potential therapeutic targets. Furthermore, human sialidases involved in important physiological functions do not express CBMs.
In this work, we developed an alternative approach to the "lock and key concept" to achieve high affinities and selectivities for sialidases (Brissonnet, Y., et al. Chem. Eur. J. 2019, 25 (9), 2358-2365). Multivalent thiosialosides were designed to bind to both the CAT and the CBM of pathogenic sialidases.
Sialidases from Vibrio cholerae, Trypanosoma cruzi and Streptococcus pneumoniae were produced with and without the CBM to determine the importance of dual targeting and the validity of the multivalent concept ( Figure 9 ). Inhibition tests of a polyvalent thiosialoside against the representative bacterial, parasitic and fungal sialidases showed inhibitory activity up to the nanomolar range with a strong synergistic effect. These results extend the multivalent concept to this important class of enzymes for which transition-state inhibitors failed to reach the submicromolar level. Phosphatidylinositol-3-kinases (PI3Ks) are lipid kinases that regulate a plethora of cellular processes including proliferation, survival and motility. PI3Ks have been divided into three classes. Of these, the most characterized is the class I enzymes, which are activated by cell surface receptors to generate phosphatidylinositol-3,4,5-trisphosphate (PIP3). Class I PI3Ks are further divided into four isoforms (α, β, γ and δ), the former two isoforms are ubiquitously expressed, whereas PI3K γ and δ are found mainly in the haematopoietic system (Schwehm, C., et al. J. Med. Chem. 2017, 60, 1534-1554). PI3K δ has been identified as an attractive drug target, where it plays a key role in the pathogenesis of blood cancer (lymphoma, leukaemia) and autoimmune disease, such as rheumatoid arthritis. Selective inhibition of PI3K δ is desired to avoid the side effects associated with the inhibition of PI3k α and β, which play a major role in insulin signalling and platelet aggregation. Idelalisib is the first approved selective PI3K δ inhibitor for the treatment of chronic lymphocytic leukaemia (CLL) and follicular lymphoma (FL). However, idelalisib has demonstrated serious side effects involving hepatic toxicity, colitis, serious diarrhoea and pneumonitis (Somoza, J., et al. J.Biol. Chem. 2015, 290, 8439-8446). Starting from a non-selective PI3K inhibitor "pictilisib", we identified a series of potent indole-based inhibitors of PI3K δ with good selectivity versus other PI3K isoformsthe high δ selectivity of these compounds could be attributed to favourable interaction with "tryptophan shelf". The "tryptophan shelf" defines the face of Trp760, that can be accessed only in PI3K δ due to movement of Thr750. On the other hand, in the other isoforms, the face of the tryptophan is "blocked" by basic residues that can form strong -cation interactions with Trp760 ( Figure 10 ). Inhibition tests of a polyvalent thiosialoside against the representative bacterial, parasitic and fungal sialidases showed inhibitory activity up to the nanomolar range with a strong synergistic effect. These results extend the multivalent concept to this important class of enzymes for which transition-state inhibitors failed to reach the submicromolar level. Phosphatidylinositol-3-kinases (PI3Ks) are lipid kinases that regulate a plethora of cellular processes including proliferation, survival and motility. PI3Ks have been divided into three classes. Of these, the most characterized is the class I enzymes, which are activated by cell surface receptors to generate phosphatidylinositol-3,4,5-trisphosphate (PIP3). Class I PI3Ks are further divided into four isoforms (α, β, γ and δ), the former two isoforms are ubiquitously expressed, whereas PI3K γ and δ are found mainly in the haematopoietic system (Schwehm, C., et al. J. Med. Chem. 2017, 60, 1534-1554). PI3K δ has been identified as an attractive drug target, where it plays a key role in the pathogenesis of blood cancer (lymphoma, leukaemia) and autoimmune disease, such as rheumatoid arthritis. Selective inhibition of PI3K δ is desired to avoid the side effects associated with the inhibition of PI3k α and β, which play a major role in insulin signalling and platelet aggregation. Idelalisib is the first approved selective PI3K δ inhibitor for the treatment of chronic lymphocytic leukaemia (CLL) and follicular lymphoma (FL). However, idelalisib has demonstrated serious side effects involving hepatic toxicity, colitis, serious diarrhoea and pneumonitis (Somoza, J., et al. J. Biol. Chem. 2015, 290, 8439-8446). Starting from a non-selective PI3K inhibitor "pictilisib", we identified a series of potent indole-based inhibitors of PI3K δ with good selectivity versus other PI3K isoforms-the high δ selectivity of these compounds could be attributed to favourable interaction with "tryptophan shelf". The "tryptophan shelf" defines the face of Trp760, that can be accessed only in PI3K δ due to movement of Thr750. On the other hand, in the other isoforms, the face of the tryptophan is "blocked" by basic residues that can form strong -cation interactions with Trp760 ( Figure 10 ).
The decline in discovery of novel antimicrobial compounds over the last two decades has become a worldwide problem (Spellberg, B., et al. Clin. Infect. Dis., 2004, 38(9), 1279-1286). With the ability of microorganisms to evolve and adapt to survive exposure to antibiotics, that is, the emergence of antimicrobial resistance (AMR), human health is severely threatened (O′Neill, J.; 2014 (Accessed: May 2019)). For instance, AMR hampers the treatment of post-surgery infections caused by bacteria such as Staphylococcus aureus, and severely complicates the healing of infected chronic wounds.
Previous work in our group showed that amino acid-functionalised dehydroabietic acid derivatives are capable of killing planktonic bacteria and limit their ability to form biofilms (a. This combination of renewability, low cost, strong structural integrity and its innate non-cytotoxic properties make it an ideal basis for development of new antimicrobial biomaterials.
The goal of our current work is to build from this knowledge and chemically modify medically relevant biopolymers with our in-house library of antimicrobial abietanes to produce materials with innate antibacterial properties and explore their potential applications in wound-healing. This combination of renewability, low cost, strong structural integrity and its innate non-cytotoxic properties make it an ideal basis for development of new antimicrobial biomaterials.
The goal of our current work is to build from this knowledge and chemically modify medically relevant biopolymers with our in-house library of antimicrobial abietanes to produce materials with innate antibacterial properties and explore their potential applications in wound-healing. Our current work aims to (1) improve the available yield for chiral resolution by determining the necessary conditions to achieve stereoselective synthesis of trans 3-hydroxy-1,4-diaryl-2-azetidinones in the Staudinger reaction and (2) provide purification of racemic mixtures using N-(tert-butoxycarbonyl)-L-Proline as a chiral resolving agent to afford optically pure enantiomers for further biological evaluation. Trans 3-hydroxy β-lactams have been separated from cis derivatives using chromatographic purification. We have since optimized the Staudinger reaction to return relative yields of 95% relative ratio of trans/cis isomers, as indicated by integration of protons at position 3 and 4 of the β-lactam on 1 H-NMR. Diastereomeric resolution using flash column chromatography followed by hydrolysis of chiral resolving agents successfully yielded enantiomers of EMCL001 and 2 ( Figure 11 ). Preliminary biochemical data for the enantiomers in breast cancer cells will be reported. Our previous research aimed at complete genome sequence of medicinal leech Hirudo medicinalis, allowing for in silico implementation of the searching algorithms to identify new biologically active peptides, such as thrombolytic, anticoagulant and antibacterial agents. We applied computational algorithms to the medicinal leech Hirudo medicinalis genome assembly and identified homologs of serine proteinase inhibitors, promising anticoagulant proteins and candidate antimicrobial peptides (AMPs). Identified AMPs were chemically synthesised and assayed antimicrobial activity against three bacterial species (Escherichia coli, Bacillus subtilis and Chlamydia thrachomatis), cytotoxic and hemolytic activities and determined their secondary structures by NMR spectroscopy. Eight peptides exhibited antimicrobial activity, and two peptides, 3967 and 536-1, reduced the survival of E. coli, B. subtilis and C. thrachomatis cells through the disruption of cellular integrity at a concentration of 10 µM. Almost all the examined AMPs exhibited low-to-moderate haemolytic activity with no effects on the viability of cultured eukaryotic cells. Moreover, it was shown that three peptides, 536_2, 12530 and 3967, adopted α-helical conformation in membrane-mimetic DPC micelles. Overall, our experimental data verify the utility of the developed computational algorithms for the discovery of potential biologically active peptides. Using developed computational algorithm, we identified two promising medicinal leech AMPs, 3967 and 536-1, which are able to be considered in perspective as therapeutic agents.
This work was supported by the Russian Science Foundation (project №17-75-20099). Chem. 2014, 57, 3623-3650 ). The hA 2A AR mainly signals through the stimulatory GPCR and, upon receptor activation, adenyl cyclase is stimulated, leading to Cyclic adenosine monophosphate cAMP accumulation. The therapeutic potential of targeting the hA 2A AR has been broadly investigated, leading to the development of an extensive number of synthetic agonists and antagonists for the treatment of several diseases including cardiovascular, inflammatory and CNS disorders. More recently, targeting the hA 2A AR has generated a great interest in cancer immunotherapy. The tumour micro-environment features high concentrations of immunosuppressive adenosine that, upon A 2A AR engagement, silences the immune response in the host, leading to tumour growth and proliferation. Indeed, A 2A AR antagonism is being investigated as a therapeutic approach to defeat the immune system evasion by the tumour (Leone, R. D., et al. J. Immunother. Cancer 2018, 6 (1), 1-9). In this regard, understanding the complexity of the adenosinergic signalling is an essential prerequisite to address and develop more efficacious therapies. This can be facilitated by exploiting fluorescent probes selectively targeting the hA 2A AR both in vitro and in vivo (Vernall, A. J., et al. iScience 2018, 6, 280-288).
Herein, we report the design synthesis and pharmacological evaluation of two generations of subtype-selective fluorescently-labelled hA 2A AR antagonists based on preladenant. Of particular interest for in vivo studies was the second generation of ligands, which features water soluble probes and, therefore, might display better stability in plasma and improved detection after IV-administration. Molecular modelling analysis has corroborated previously reported SAR studies indicating the optimal position for fluorophore attachment. The newly synthesised fluorescent probes retained functional activity and binding affinity at the hA 2A AR, displaying a selectivity of >1000 nM over the other receptor subtypes. The effectiveness of the probes as pharmacological tools was also investigated in high resolution confocal imaging studies, revealing specific co-localisation with SNAP-hA 2A AR at the cell membrane, which was surmounted by incubating the cells with high concentration of unlabelled ligand. In conclusion, given their excellent pharmacological and photochemical properties, the reported novel fluorescent ligands embody valuable tools to study the signalling and dynamics of the hA 2A AR, not only in vitro but also in vivo, providing a robust and specific platform for further drug discovery investigations. The first developments and biological results of this novel series of molecules will be discussed. The authors would like to acknowledge Capes/Cofecub Program France-Brazil Me 865-15 for financial support. As a result, inhibiting STAT5 would contribute to reduce the survival of CML and AML cells and moreover tackle their potential chemoresistance. A first structure-activity relationship study allowed us to identify one compound, 17f ( Figure  13) , which inhibited the growth of AML and CML cell lines as well as phosphorylation and As a result, inhibiting STAT5 would contribute to reduce the survival of CML and AML cells and moreover tackle their potential chemoresistance.
Synthesis and Biological Evaluation of Inhibitors Targeting Signal Transducers and Activators of Transcription 5 (STAT5) Proteins in Myeloid Leukemias (P15)
Marion Polomski 1 , Marie Brachet-Botineau 2 , Ludovic Juen 1 , Fabrice Gouilleux 2 , Marie-Claude Viaud-Massuard 1 and Gildas Prié 1
A first structure-activity relationship study allowed us to identify one compound, 17f (Figure 13 ), which inhibited the growth of AML and CML cell lines as well as phosphorylation and transcriptional activity of STAT5. These results suggest that 17f might be a new lead molecule targeting STAT5 signalling in myeloid leukemias (Juen, et al. J. Med. Chem. 2017, 60, 6119-6136). Thanks to these results, synthesis of 17f new analogues with modulation around the tetrahydroquinoleine (THQ) ring were undertaken and their biological evaluation was carried out on model CML (KU812, K562) and AML (MV-4-11) cell lines. Among these new results, one compound, with the 4-pyridinyl in position 5 on the THQ ring, showed slightly better results than 17f on all cell lines. This outcome will guide further modulation work on the THQ ring with others nitrogen heterocycles (pyridazine, triazine, etc.). 2911-2915). AML results mainly from internal tandem duplication (Itd) mutations in the juxtamembrane region or point mutation in fms like tyrosine kinase 3, FLT3. This oncoprotein FLT3-Itd (internal tandem duplication) has a tyrosine kinase activity, which activates STAT5 (Birkenkamp, et al. Leukemia 2001 , 15, 1923 -1931 .
As a result, inhibiting STAT5 would contribute to reduce the survival of CML and AML cells and moreover tackle their potential chemoresistance. A first structure-activity relationship study allowed us to identify one compound, 17f ( Figure  13) , which inhibited the growth of AML and CML cell lines as well as phosphorylation and Plant secondary metabolism produces a large number of specialized compounds (over 300,000) including terpenoids, alkaloids and (poly)phenols. Often referred to as "natural products" (NPs), many of these compounds are used for medicinal, cosmetical and/or nutraceutical purposes. Apple trees (Malus x domestica Brokh.) are widely cultivated all around the world, and apple is the first fruit to be produced in Europe. In France, the "Région des Pays de la Loire" appears as the second national producer of apples, with apple trees being the main cultivated surface in this area. Apple fruits/trees are characterized with a cell specific accumulation-in different tissues-of varying levels of bioactive polyphenols including proanthocyanidins, anthocyanins, flavonols and dihydrochalcones (DHCs) ( Figure 14 ). Thanks to these results, synthesis of 17f new analogues with modulation around the tetrahydroquinoleine (THQ) ring were undertaken and their biological evaluation was carried out on model CML (KU812, K562) and AML (MV-4-11) cell lines. Among these new results, one compound, with the 4-pyridinyl in position 5 on the THQ ring, showed slightly better results than 17f on all cell lines. This outcome will guide further modulation work on the THQ ring with others nitrogen heterocycles (pyridazine, triazine, etc.).
From Phloridzin towards Semisynthetic Bioactive Dihydrochalcones (P16)
A Plant secondary metabolism produces a large number of specialized compounds (over 300,000) including terpenoids, alkaloids and (poly)phenols. Often referred to as "natural products" (NPs), many of these compounds are used for medicinal, cosmetical and/or nutraceutical purposes. Apple trees (Malus x domestica Brokh.) are widely cultivated all around the world, and apple is the first fruit to be produced in Europe. In France, the "Région des Pays de la Loire" appears as the second national producer of apples, with apple trees being the main cultivated surface in this area. Apple fruits/trees are characterized with a cell specific accumulation-in different tissues-of varying levels of bioactive polyphenols including proanthocyanidins, anthocyanins, flavonols and dihydrochalcones (DHCs). The main goal of this project is to (semi-)synthesize original DHCs, in particular, C-benzylated derivatives, starting from phloridzin or sieboldin extracted from locally produced apple tree leaves as renewable sources. The semi-synthetic analogues will then be submitted to biological assays to evaluate their anti-tumoural potential. Endogenous catecholamines (e.g., adrenaline) and conventional agonists (e.g., isoprenaline and cimaterol) mediate a response mainly through the primary conformation. Other ligands (e.g., CGP12177 1) mediate a response through the secondary conformation, even though the concentration required to stimulate this response is considerably greater than the concentration required to bind the primary conformation (Pak, M.D., et al. J. Recept Signal Transduct Res., 1996, 16, 1-23). Alprenolol (2) stimulates a response through both conformations and it also requires higher concentrations to activate the secondary conformation (Baker, J.G., et al. Mol. Pharmacol, 2003, 63, 1312-1321). To date, no ligand has been reported that binds the secondary conformation with higher affinity than the primary conformation.
Alprenolol bis analogue 3 has been previously identified as the first sub-micromolar compound to have similar affinity for both conformations (Sousa, E.P, et al. 2018, Poster presented at EFMC-ISMC 2018). In order to identify the molecular descriptors responsible for the interaction and activation of the secondary conformation of the β 1 -AR, several analogues were synthesised and pharmacologically characterised through competitive radioligand binding assays and cAMP reporter gene (CRE-SPAP) functional assays. In this communication, we report the affinity of these analogues for both conformations of the β 1 -AR. Med. 2013, 79, 83-86). Therefore this series of compounds is of high interest because of their pharmacological potential. The main goal of this project is to (semi-)synthesize original DHCs, in particular, C-benzylated derivatives, starting from phloridzin or sieboldin extracted from locally produced apple tree leaves as renewable sources. The semi-synthetic analogues will then be submitted to biological assays to evaluate their anti-tumoural potential. Endogenous catecholamines (e.g., adrenaline) and conventional agonists (e.g., isoprenaline and cimaterol) mediate a response mainly through the primary conformation. Other ligands (e.g., CGP12177 1) mediate a response through the secondary conformation, even though the concentration required to stimulate this response is considerably greater than the concentration required to bind the primary conformation (Pak, M.D., et al. J Recept Signal Transduct Res., 1996, 16, 1-23). Alprenolol (2) stimulates a response through both conformations and it also requires higher concentrations to activate the secondary conformation (Baker, J.G., et al. Mol. Pharmacol, 2003, 63, 1312-1321 ). To date, no ligand has been reported that binds the secondary conformation with higher affinity than the primary conformation.
Alprenolol bis analogue 3 has been previously identified as the first sub-micromolar compound to have similar affinity for both conformations (Sousa, E.P, et al. 2018, Poster presented at EFMC-ISMC 2018). In order to identify the molecular descriptors responsible for the interaction and activation of the secondary conformation of the β1-AR, several analogues were synthesised and pharmacologically characterised through competitive radioligand binding assays and cAMP reporter gene (CRE-SPAP) functional assays. In this communication, we report the affinity of these analogues for both conformations of the β1-AR. Aqueous microgels based on poly(N-vinylcaprolactam) with reversable temperature-induced volume transition are promising "smart" materials for various applications, in particular for drug delivery (Saunders, B. R., et al. Adv. Colloid. Interfac. 2009, 147-48, 251-262) . Here, the aqueous microgels are modified via acid-base interaction by ligand molecules. They are wedge-shaped amphiphilic sulfonic acid molecules with an azobenzene grou and alkyl chains of different lengths. Modified microgels remain colloidally stabile in water and show different responses to the change of temperature and pH within the physiologic condition (Grafskaia, K. N., et al. Chem . Commun. 2017,  53, 13217) . The hydrophobicity of the microgel interior increases with the increase of the modification degree. Hardening of hydrophobic nanodomains and a decrease of the hydrodynamic diameter for sample complexed with C8AzoSO3H at the highest neutralization degrees can be explained by formation of the alkyl sub-lattice ( Figure 15 ). Triple negative breast cancer (TNBC) is the most aggressive form of breast cancer. It accounts for approximately 20% of all breast cancers and has an increased rate of relapse compared to non-TNBCs. This aggressive nature is due to its lack of receptors for targeted therapies and thus results Triple negative breast cancer (TNBC) is the most aggressive form of breast cancer. It accounts for approximately 20% of all breast cancers and has an increased rate of relapse compared to non-TNBCs. This aggressive nature is due to its lack of receptors for targeted therapies and thus results in chemotherapy being the only option for treatment (Gonçalves Jr, H., et al. Clin. Med. In. Onc.  2018, 12, 1-10) . This reveals the need to investigate other means for targeting and treating TNBC, more specifically, through the use of small molecule inhibitors. We discovered that dual specificity tyrosine(Y) regulated kinase-2 (DYRK2) stabilises heat shock factor-1 (HSF1), the master regulator of proteotoxic stress pathways (Rashmi, K. C., et al. Cell Stress and Chaperones, 2017, 22, 751-766 ). In addition, we showed that low DYRK2 expression correlates with an increased survival rate in TNBC patients ( Figure 16A ). . Onc. 2018,  12, 1-10) . This reveals the need to investigate other means for targeting and treating TNBC, more specifically, through the use of small molecule inhibitors. We discovered that dual specificity tyrosine(Y) regulated kinase-2 (DYRK2) stabilises heat shock factor-1 (HSF1), the master regulator of proteotoxic stress pathways (Rashmi, K. C., et al. Cell Stress and Chaperones, 2017, 22, 751-766 ). In addition, we showed that low DYRK2 expression correlates with an increased survival rate in TNBC patients ( Figure 16A ). To date, there are no selective small molecule inhibitors for DYRK2. With the aid of molecular modelling, we developed an SAR profile of DYRK2 inhibitors, with our most potent inhibitor being LB35 Ki 19 nM ( Figure 16B ). These inhibitors revealed an impressive selectivity profile, whereby a structurally similar compound showed <30% inhibition against a panel of 40 structurally related kinases. Within this poster, we aim to describe our ongoing efforts to provide an inhibitor for DYRK2 with increased potency and examine the DMPK challenges associated with this inhibitor series. The loss of a ligand′s entropy upon receptor binding can be reduced by rigidification of its chemical structure, often leading to enhanced potency, depending on whether the bioactive conformation is matched or not. Conformational restriction can also induce selectivity for receptor subtypes, as slightly different shapes of orthosteric binding pockets may require a different conformational adaption of the ligand. Taking advantage of those effects can lead to the development of novel molecular probes for scientific research and medications with improved pharmacodynamic or pharmacokinetic properties (Ring, et al. Nature. 2013, 502, 575-579 ).
Representative compounds
Synthesis of Conformationally Restricted Adrenaline Analogs Selectively Activating β2-AR with
Using the pharmacologically important target β2-AR, we aimed at synthetically constraining highly flexible agonists of the catecholamine type into their bioactive conformation. Thus, we To date, there are no selective small molecule inhibitors for DYRK2. With the aid of molecular modelling, we developed an SAR profile of DYRK2 inhibitors, with our most potent inhibitor being LB35 Ki 19 nM ( Figure 16B ). These inhibitors revealed an impressive selectivity profile, whereby a structurally similar compound showed <30% inhibition against a panel of 40 structurally related kinases. Within this poster, we aim to describe our ongoing efforts to provide an inhibitor for DYRK2 with increased potency and examine the DMPK challenges associated with this inhibitor series. The loss of a ligand s entropy upon receptor binding can be reduced by rigidification of its chemical structure, often leading to enhanced potency, depending on whether the bioactive conformation is matched or not. Conformational restriction can also induce selectivity for receptor subtypes, as slightly different shapes of orthosteric binding pockets may require a different conformational adaption of the Using the pharmacologically important target β 2 -AR, we aimed at synthetically constraining highly flexible agonists of the catecholamine type into their bioactive conformation. Thus, we synthesized a set of eight different isomers of ethylene bridged isoprenaline, with one of them ("super-iso") being clearly superior regarding affinity, potency and selectivity for β 2 over β 1 . Super-epi, super-norepi, etc., refer to compounds with the same constitution and stereochemical configuration (Figure 17 ). Structural insights into the receptor state and the binding poses of super-epi and super-iso were obtained by co-crystal structures of β2-AR bound to Nb6B9.
The poster will also give information about efficient chemical synthesis, biological investigations and structure-activity relationships (SAR) of the conformationally restricted catecholamines. The pulmonary drug delivery route possesses significant benefits over other administrative routes, including targeted delivery to the site of action, by-pass of first pass metabolism in the liver and fewer side effects owing to a reduced drug dosage. However, rapid drug elimination from lung tissue in to the hepatic vein and the pan antagonistic nature of receptor antagonists often leads to increased side effects. By exploiting the highly lung retentive nature of dibasic compounds, it is possible to reduce the rate of elimination from the lungs and thus reduce side effects. This work describes the design and synthesis of a range of dibasic prodrugs that have the potential to be lysosomally trapped within lung tissue and cleave slowly at a desired pH to effectively deliver an active drug at a slower more consistent rate. The pulmonary drug delivery route possesses significant benefits over other administrative routes, including targeted delivery to the site of action, by-pass of first pass metabolism in the liver and fewer side effects owing to a reduced drug dosage. However, rapid drug elimination from lung tissue in to the hepatic vein and the pan antagonistic nature of receptor antagonists often leads to increased side effects. By exploiting the highly lung retentive nature of dibasic compounds, it is possible to reduce the rate of elimination from the lungs and thus reduce side effects. This work describes the design and synthesis of a range of dibasic prodrugs that have the potential to be lysosomally trapped within lung tissue and cleave slowly at a desired pH to effectively deliver an active drug at a slower more consistent rate. We aim to develop a new series of flavones for application against breast cancer. Two previously identified flavone leads (1 and 2 in scheme 2 from which new selenium and ruthenium derivatives can be synthesized). The synthesis provides molecular frameworks, following a Baker-Venkataraman rearrangement pathway.. This will be followed by in vitro cytotoxicity and antiangiogenic assessments in addition to probing the possible mechanisms of action of the most active compounds. We aim to develop a new series of flavones for application against breast cancer. Two previously identified flavone leads (1 and 2 in Scheme 3 from which new selenium and ruthenium derivatives can be synthesized). The synthesis provides molecular frameworks, following a Baker-Venkataraman rearrangement pathway.. This will be followed by in vitro cytotoxicity and anti-angiogenic assessments in addition to probing the possible mechanisms of action of the most active compounds. According to a recent report from the World Health Organization (WHO), leishmaniasesvisceral leishmaniasis (VL), cutaneous leishmaniasis (CL) and mucocutaneous leishmaniasis (MCL) -collectively affect 12 million people in 98 countries, 350 million more are at risk of infection and 40,000 deaths are attributed to leishmaniases each year . Currently, there are no effective vaccines and a number of drugs are used in the treatment of these parasitic infections: pentavalent antimonials, amphotericin B, miltefosine, pentamidine, paromomycin and sitamaquine (Sangshetti, J.N., et al. RSC Adv. 2015, 5, 32376-32415) . Unfortunately, most of them cause side effects and high toxicities, and an inevitable resistance has developed in recent times in Leishmania parasites. Consequently, there is an urgent need to speed up the development of a new generation of more effective and safe antileishmanials.
Design and Synthesis of Novel Flavone Derivatives as Anti-Cancer Agents (P22)
Mai Khater, a Francesca Greco
Imidazo [1, 2-a] Pyrazines Displaying In Vivo Antileishmanial Activity (P23)
Marc-Antoine Bazin 1 , Sandrine Cojean 2 , Fabrice Pagniez 1 , Marie-Renée Nourrisson 1 , Carine Picot 1 , Christian Cavé 2 , Guillaume Bernadat 2 , Stéphane Bach 3 , Najma Rachidi 4 , Olivier Leclercq 4 , Philippe Loiseau 2 , Patrice Le Pape 1 and Pascal Marchand 1
In the course of our ongoing synthetic and screening programs for the obtention of new biologically active imidazo [1, 2-a] azines, we decided to develop bioisostere analogues of the previously described 2,3-diarylimidazo[1,2-a]pyridines as antileishmanial agents (Marhadour, S., et al. Eur. J. Med. Chem. 2012, 58, 543-556).
Two promising analogues were highlighted as hit compounds (Figure 18 The mechanism of action involved in the antiparasitic properties will be discussed, as 4-pyridyl moiety at the C-3 position of the heterocyclic core was associated with L. major casein kinase 1 (LmCK1) inhibition, validated as a potential molecular target for antileishmanial drug development (Durieu, E., et al. Antimicrob. Agents Chemother. 2016, 60, 2822-2833). The X-linked inhibitor of apoptosis protein (XIAP) binds to and inhibits caspases 3, 7 and 9, which are some of the enzymes responsible for cell death, and therefore stopping apoptosis. XIAP is naturally regulated (inhibited) by the mitochondrial protein SMAC/DIABLO. However, XIAP is overexpressed in tumorous cells (particularly in ovarian cancer) making them resist cell death. This is why XIAP makes a suitable drug target.
Inhibiting X-Linked Inhibitor of Apoptosis Protein (XIAP), Design of New Non-Peptidic Foldamers of SMAC (P24)
Meziane Yahia-Ouahmed, Martin Giret, Kévin Antraygues, Marie Jouanne, Charline Kieffer and Jana Sopkova-de Oliveira Santos
The project aims at designing new non-peptidic inhibitors of XIAP in order to promote apoptotic cell death in ovarian tumours. This could be done by "mimicking" the AVPI tetra-peptide of SMAC (β strand) that is used by the latter to bind to the BIR3 domain of XIAP.
First, a pharmacophore model was built on the basis of two ligands of XIAP-BIR3 found in the literature. Then, a series of compounds were designed. The binding of these compounds to the active site was studied by molecular docking. Molecular dynamics simulations were then performed to assess the stability of the ligands in the active site. The best compounds were synthetized and tested in-vitro by fluorescence polarisation assay (FPA). The most promising candidates were selected in order to carry out new pharmacomodulations. The mechanism of action involved in the antiparasitic properties will be discussed, as 4-pyridyl moiety at the C-3 position of the heterocyclic core was associated with L. major casein kinase 1 (LmCK1) inhibition, validated as a potential molecular target for antileishmanial drug development The X-linked inhibitor of apoptosis protein (XIAP) binds to and inhibits caspases 3, 7 and 9, which are some of the enzymes responsible for cell death, and therefore stopping apoptosis. XIAP is naturally regulated (inhibited) by the mitochondrial protein SMAC/DIABLO. However, XIAP is overexpressed in tumorous cells (particularly in ovarian cancer) making them resist cell death. This is why XIAP makes a suitable drug target.
First, a pharmacophore model was built on the basis of two ligands of XIAP-BIR3 found in the literature. Then, a series of compounds were designed. The binding of these compounds to the active site was studied by molecular docking. Molecular dynamics simulations were then performed to assess the stability of the ligands in the active site. The best compounds were synthetized and tested in-vitro by fluorescence polarisation assay (FPA). The most promising candidates were selected in order to carry out new pharmacomodulations.
University of Nottingham, Nottingham, Nottinghamshire NG7 2RD, UK; paxrll@nottingham.ac.uk Current antibiotic treatments for P. aeruginosa infections have proven ineffective due to the increasing rate of resistance to them. Inhibitors of the pqs quorum sensing signalling, key for the control of virulence, have been regarded as a promising alternative (Melissa, S., et al. PLoS. Pathog. 2014, 10, e1004321).
In this work, we report the discovery, design, synthesis and biological evaluation of a series of novel inhibitors of the PqsR regulatory protein, key for the activation of the pqs system, resulting in the identification of compound 2. The initial hit compound 1 (IC 50 = 0.98 µM) was obtained through a virtual screening performed on PqsR ligand-binding domain using an in-house compound library (Figure 19a ). Exploration of compound 1 gave the first generation of compounds evaluated using both PAO1-L mCTX: P pqsA -lux and PA14 mCTX: P pqsA -lux P. aeruginosa pqs bioreporter strains. Further structure activity exploration, to improve potency and physiochemical properties, gave a second generation of compounds with improved inhibitory activity. Notably, the introduction of an electron deficient tail group gave compound 2 (IC 50 = 0.25 µM), one of the most potent known pqs inhibitors to date. The crystallization of compound 2 in PqsR ligand binding domain was obtained (Figure 19b ) and detailed SAR studies of this series of compounds will be discussed in the poster. Current antibiotic treatments for P. aeruginosa infections have proven ineffective due to the increasing rate of resistance to them. Inhibitors of the pqs quorum sensing signalling, key for the control of virulence, have been regarded as a promising alternative (Melissa, S., et al. PLoS. Pathog.  2014, 10, e1004321) .
In this work, we report the discovery, design, synthesis and biological evaluation of a series of novel inhibitors of the PqsR regulatory protein, key for the activation of the pqs system, resulting in the identification of compound 2. The initial hit compound 1 (IC50 = 0.98 µM) was obtained through a virtual screening performed on PqsR ligand-binding domain using an in-house compound library (Figure 19a ). Exploration of compound 1 gave the first generation of compounds evaluated using both PAO1-L mCTX: PpqsA-lux and PA14 mCTX: PpqsA-lux P. aeruginosa pqs bioreporter strains. Further structure activity exploration, to improve potency and physiochemical properties, gave a second generation of compounds with improved inhibitory activity. Notably, the introduction of an electron deficient tail group gave compound 2 (IC50 = 0.25 µM), one of the most potent known pqs inhibitors to date. The crystallization of compound 2 in PqsR ligand binding domain was obtained (Figure 19b ) and detailed SAR studies of this series of compounds will be discussed in the poster.
(a) (b) Figure 19 . General structure of compounds and PqsR. Invest. 2010, 120, 1774-1785 ). On the basis of the main structural features of the LM22A-4, we designed a small dataset of the new potential TrkB agonists and conducted the synthesis of the compounds with best in silico results.
In Silico Screening and Development of Small Molecule Neurotrophin Receptor Ligands (P26)
Mirjana Antonijevic, Ronan Bureau, Patrick Dallemagne and Christophe Rochais
This project received funding from the European Union′s Horizon 2020 framework programme for research and innovation under grant agreement no. 765704.
Isolation and Structure Elucidation of Aspergillus Metabolites Induced with Epigenetic Modulators (P27)
Mohammed Aldholmi 1,2 and A. Ganesan 1 1 School of Pharmacy, University of East Anglia, Norwich Research Park, Norwich NR4 7TJ, United Kingdom. Five Aspergillus strains were cultivated in the presence of Histone Deacetylase Activity (HDAC) inhibitors (e.g., vorinostat) or DNA methyltransferase (DNMT) inhibitors (e.g., 5-azacytidine). Five Aspergillus strains were cultivated in the presence of Histone Deacetylase Activity (HDAC) inhibitors (e.g., vorinostat) or DNA methyltransferase (DNMT) inhibitors (e.g., 5-azacytidine). Morphological changes were monitored for 7 days before extraction with ethyl acetate or methanol. The extracts were analysed by HPLC and LC-MS, and the metabolic profiles were compared using chromatogram overlay and volcano plots.
The overlayered chromatograms and volcano plots presented significant differences between the cultures treated with epigenetic modifiers and control cultures. Two induced bioactive metabolites were isolated from Aspergillus westerdijkiae and Aspergillus calidoustus, and their structures were elucidated using mass spectrometry and NMR.
I would like to thank Imam Abdulrahman Bin Faisal University for their financial support. Accordingly with these results, we prepared new 2-trichloromethylquinoxaline analogues bearing other electron-withdrawing groups such as -CF3, -SF5 or -OCF3.
In parallel, to complete the global SAR study using the scaffold hopping approach, we replaced the quinoxaline ring with a phthalazine one. The importance for the antiplasmodial activity of the phenyl ring contained in the bicyclic quinazoline and quinoxaline scaffolds was also studied by structural simplification, leading to the related pyrimidine and pyrazine analogues. The synthesis details of the new analogues of hit 1 in various series and the biological results will be described in the poster. The histamine H1 receptor (H1R) is a class A GPCR and is widely expressed throughout the human body. H1R-dependent signalling is responsible for allergic reactions, plays an important role in immunomodulation and, as recent studies have suggested, is involved in mediating cell proliferation and thus cancer progression (Panula, P., et al. Pharmacol Rev. 2015, 67 (3) , 601-655). High affinity H1R fluorescent ligands with optimum physicochemical properties would serve as a valuable In parallel, to complete the global SAR study using the scaffold hopping approach, we replaced the quinoxaline ring with a phthalazine one. The importance for the antiplasmodial activity of the phenyl ring contained in the bicyclic quinazoline and quinoxaline scaffolds was also studied by structural simplification, leading to the related pyrimidine and pyrazine analogues. The synthesis details of the new analogues of hit 1 in various series and the biological results will be described in the poster.
This work was supported by the ANR NINTARMAL project, grant ANR-17-CE11-0017. We envisaged optimising the peptide linker for a previously reported H 1 R fluorescent ligand (Stoddart, L. A., et al. Scientific Reports 2018, 8 (1), 1572) with pK D of 8.1 by sequential screening for amino acids along the peptide chain in order to identify those that could provide the greatest improvement in binding affinity. By incorporating these amino acids into the linker, we synthesised H 1 R fluorescent ligands with pK D s ranging from 7.8 to 8.4. Molecular docking of these ligands into an H 1 R crystal structure suggested the existence of small binding pockets along the receptor exit tunnel that were exploited by the functionalised peptide linkers. Further experimentation with fluorescent ligands of varying fluorophores suggested that the attachment of the boron-dipyrromethene BODIPY630/650 fluorophore was the main driving force in binding affinity in H 1 R fluorescent ligands. Despite not being able to significantly improve binding affinities of H 1 R fluorescent ligands, optimisation of the peptide linker provided information on SAR along the receptor exit tunnel. In 2018, the number of people living with dementia in the world was estimated at 50 million, and Alzheimer s disease (AD) is the most common form of dementia. AD is a neurodegenerative and incurable brain disorder; only treatments for symptoms are available at this time. Because of the heavy economic and societal impacts, there is an urgent need to find new treatments that target the molecular causes of neuronal cell death. Two abnormal structures in the brain called β-amyloid (Aβ)-containing plaques and neurofibrillary tangles are considered as two of the main features of AD. In this context, several studies support the hypothesis that alterations in the processing of amyloid precursor protein (APP) contributes to AD pathogenesis, resulting in the accumulation of β-amyloid peptides (Aβ) and other proteolytic products. Thus, current research focuses on the enzymes involved in APP cleavage such as α-, βand γ-secretases. However, recent studies have revealed the existence of another physiological APP processing pathway, mediated by a novel AD-related enzyme, membrane-type 5-matrix metalloproteinase (MT5-MMP), which can process APP and promote Aβ accumulation, as well as the inflammatory process in AD transgenic mice (Baranger, K., et al. Cell. Mol. Life Sci.
Malaria is an infectious disease caused by the parasite of the genus Plasmodium with human infection caused by species falciparum, malaria, knowlesi, vivax and ovale (De Koning-ward, T. F., et al. Nat. Publ. Gr. 2016, 14, 494-507). P. falciparum is associated with the most severe form of malaria, responsible for ≈400,000 deaths/year, especially in Africa. A number of antimalarial drugs are currently used to treat malaria. However, P. falciparum has developed resistance to all currently used medicines, hence, there is a great need for the development of new drugs. Here, we report novel quinolines as antimalarial leads. The quinolines were originally designed to be inhibitors of NRH-quinone oxidoreductase 2 (NQO2), a potential therapeutic target in cancer chemotherapy (Alnabulsi, S., et al. Bioorg. Med. Chem. Lett. 2018; 9, 1-6). P. falciparum contains a functionally similar type II NADH/dehydrogenase known as Pf NDH2; therefore, these compounds were tested against Plasmodium falciparum as antimalarial leads. The quinolines were identified as a potent in vitro inhibitor of the multi-drug-resistant strain K1 of P. falciparum (with EC 50 ranging from 0.5-20 µM). The EC 50 speed assays carried out to verify onset of antimalarial activity showed that the compounds were fast-acting, as the EC 50 values were achieved at 24 h. Cell cytotoxicity assays showed that the compounds were very toxic towards HepG2 hepatic cancer cell lines seeded at 4000 cells/well, with low selectivity indices (SI 0.6-2.7). The compounds were screened further against MDBK bovine kidney cells, which showed improved selectivity indices (SI 1.6 > 10). To achieve further dose reduction and to minimize toxicity, Calcusyn-based drug interactivity assays are ongoing. Further studies are in progress to characterize stage specificity, mechanism of action, cytotoxicity profiles and drug interaction with existing antimalarial drugs.
Since its discovery in 1988, the serotonin 4 receptor subtype (5-HT 4 R) has emerged as a promising target for drug discovery and development, resulting from their implications in learning, cognition, memory processes and many neuropsychiatric disorders such as Alzheimer s disease, anxiety, depression or anorexia nervosa (Bockaert, J., et al. Since its discovery in 1988, the serotonin 4 receptor subtype (5-HT4R) has emerged as a promising target for drug discovery and development, resulting from their implications in learning, cognition, memory processes and many neuropsychiatric disorders such as Alzheimer′s disease, anxiety, depression or anorexia nervosa (Bockaert, J., et al. This synthesis was carried out in three essential steps. A convergent synthesis pathway to obtain cold ligands (CL) was established. A methodology allowing selective functionalization at position 3 leading to polyfunctional indazoles in a few steps was developed. New pharmacomodulations studies were realized in order to increase receptor affinity, decrease lipophilicity and increase metabolic resistance. More than 20 compounds with nanomolar affinity were synthesized. One of them, MR35806, is currently radiolabeled with fluorine 18 to obtain our first brain 5-HT4R PET tracer. This compound will be tested in vivo on mouse brain.
The authors are grateful for the financial support by regional council of Normandy, FEDER and Crunch Network. This synthesis was carried out in three essential steps. A convergent synthesis pathway to obtain cold ligands (CL) was established. A methodology allowing selective functionalization at position 3 leading to polyfunctional indazoles in a few steps was developed. New pharmacomodulations studies were realized in order to increase receptor affinity, decrease lipophilicity and increase metabolic resistance.
More than 20 compounds with nanomolar affinity were synthesized. One of them, MR35806, is currently radiolabeled with fluorine 18 to obtain our first brain 5-HT 4 R PET tracer. This compound will be tested in vivo on mouse brain.
The authors are grateful for the financial support by regional council of Normandy, FEDER and Crunch Network. 2010, 31, 634-640 ). Twelve phenylspirodrimanes and three triphenylphenoles were investigated on inhibitory activity towards CK2 using a capillary electrophoresis-based assay (Jagels, A., et al. Mycotoxin Res. 2018, 34, 179-185) . Triphenyl phenolestachybotrychromene C, phenylspirodrimanes stachybotrydial acetate and acetoxystachybotrydial acetate with IC 50 values of 0.3 µM, 0.7 µM and 1.9 µM, respectively, were identified as potent CK2 inhibitors ( Figure 23 ). The effect of these compounds on the proliferation of breast cancer cells MCF-7 was determined using an EdU (5-ethynyl-2'-deoxyuridine) assay. For comparison, viability of breast cancer cells is shown below. Figure 23 ). The effect of these compounds on the proliferation of breast cancer cells MCF-7 was determined using an EdU (5-ethynyl-2'-deoxyuridine) assay. For comparison, viability of breast cancer cells is shown below.
Acetoxystachybotrydial acetate
Stachybotrychromene C Figure 23 . 2D representation of the interaction between the ATP binding site of CK2 with acetoxystachybotrydial acetate and stachybotrychromene C.
Cancer cells MCF-7 as well as lung cancer cells A427 and epidermal cancer cells A 431 were tested using MTT assay. In particular, acetoxystachybotrydial acetate turned out to be the most active compound. After treatment of MCF-7 cells with 1 µM for 24 h, cell proliferation was blocked almost completely (99%), whereas cell viability was decreased only by 63%. Here, we describe phenlyspirodrimanes as a new class of CK2 inhibitors, among them acetoxystachybotrydial acetate which has been proven to be the most potent representative of this series.
Synthesis and Biological Evaluation of New Indolo [2, 3-b] Quinoline Derivatives as Potential Antimalarial Candidates (P34)
Ludovic Doudet 1 , Ingrid Allart-Simon 1 , Alexandre Maciuk 2 , Janos Sapi 1 and Stéphane Gérard 1 1 Université de Reims Champagne-Ardenne, Institut de Chimie Moléculaire de Reims (ICMR), UMR CNRS 7312, UFR Pharmacie, 51 rue Cognacq-jay, 51096 Reims, France. Cancer cells MCF-7 as well as lung cancer cells A427 and epidermal cancer cells A 431 were tested using MTT assay. In particular, acetoxystachybotrydial acetate turned out to be the most active compound. After treatment of MCF-7 cells with 1 µM for 24 h, cell proliferation was blocked almost completely (99%), whereas cell viability was decreased only by 63%. Here, we describe phenlyspirodrimanes as a new class of CK2 inhibitors, among them acetoxystachybotrydial acetate which has been proven to be the most potent representative of this series. Bile acids have conventionally been thought of as mere digestive surfactants that assist in the absorption of fats and fat soluble vitamins. In the past two decades, it has emerged that bile acids play important functions as signalling molecules in mammalian physiology and that, for example, they can regulate bile acid metabolism. FXR, a member of nuclear receptor superfamily, plays a crucial role in regulating bile acid homeostasis (Kullak-Ublick, G.A., et al. Physiology. 2008, 23(5) , 286-295) and an abundance of evidence suggests that FXR may be a useful target in the prevention of colon carcinogenesis (Modica, S., et al. Cancer Res. 2008, 23, 9589-9595 ). It can be hypothesised that isobile acids (the 3β-OH isomers of the normally occurring bile acids) can activate the FXR and regulate FXR function through their presence in the bowel and isobile acids can modify the toxicity of the bile acids (Figures 25 and 26) .
We explored new synthetic approaches for producing isobile acids from natural bile acids, and a panel of isobile acids and normal bile acids were prepared in order to help in the characterization of their effect on cellular toxicity and on FXR activation. Bile acids have conventionally been thought of as mere digestive surfactants that assist in the absorption of fats and fat soluble vitamins. In the past two decades, it has emerged that bile acids play important functions as signalling molecules in mammalian physiology and that, for example, they can regulate bile acid metabolism. FXR, a member of nuclear receptor superfamily, plays a crucial role in regulating bile acid homeostasis (Kullak-Ublick, G.A., et al. Physiology. 2008, 23(5), 286-295) and an abundance of evidence suggests that FXR may be a useful target in the prevention of colon carcinogenesis (Modica, S., et al. Cancer Res. 2008, 23, 9589-9595). It can be hypothesised that isobile acids (the 3β-OH isomers of the normally occurring bile acids) can activate the FXR and regulate FXR function through their presence in the bowel and isobile acids can modify the toxicity of the bile acids (Figures 25 and 26) .
We explored new synthetic approaches for producing isobile acids from natural bile acids, and a panel of isobile acids and normal bile acids were prepared in order to help in the characterization of their effect on cellular toxicity and on FXR activation.
We reached the conclusion that among the natural bile acids, CDCA was found to be the most toxic, followed by LCA, CA and DCA. UDCA was least toxic, and this was as expected from many studies on the relative toxicity of the bile acids, corresponding to the order of hydrophobicity of the bile acids. In general, the beta compounds (isobile acids) were less toxic than the alpha compounds. Only in the case of LCA was there no difference in the toxicity of the epimeric pairs. Only isoCDCA was found as a true FXR agonist on the basis of FXR FRET assay, whereas CDCA showed no significant effect in FRET, which was surprising. We reached the conclusion that among the natural bile acids, CDCA was found to be the most toxic, followed by LCA, CA and DCA. UDCA was least toxic, and this was as expected from many studies on the relative toxicity of the bile acids, corresponding to the order of hydrophobicity of the bile acids. In general, the beta compounds (isobile acids) were less toxic than the alpha compounds. Only in the case of LCA was there no difference in the toxicity of the epimeric pairs. Only isoCDCA was found as a true FXR agonist on the basis of FXR FRET assay, whereas CDCA showed no significant effect in FRET, which was surprising.
We are most grateful to Dr. John O′Brien for NMR spectroscopy, Gary Hessman and Brian Talbot for MS spectroscopy and Tarek Moustafa for his collaboration in the FXR FRET assay. Adv. 2014, 4 (21) , 10879-10893). To access the required 2oxoindolylacetonitrile derivatives III (Figure 27 ), we decided to explore a new route based on the We reached the conclusion that among the natural bile acids, CDCA was found to be the most toxic, followed by LCA, CA and DCA. UDCA was least toxic, and this was as expected from many studies on the relative toxicity of the bile acids, corresponding to the order of hydrophobicity of the bile acids. In general, the beta compounds (isobile acids) were less toxic than the alpha compounds. Only in the case of LCA was there no difference in the toxicity of the epimeric pairs. Only isoCDCA was found as a true FXR agonist on the basis of FXR FRET assay, whereas CDCA showed no significant effect in FRET, which was surprising.
Synthesis and Biological Activities of New 2-Mercapto-(2-Oxoindolin-3-ylidene)acetonitrile Derivatives (P36)
Boris Letribot, Régis Delatouche, Jean-René Chérouvrier, Lisianne Domon and Valérie Thiéry
We are most grateful to Dr. John O′Brien for NMR spectroscopy, Gary Hessman and Brian Talbot for MS spectroscopy and Tarek Moustafa for his collaboration in the FXR FRET assay. Adv. 2014, 4 (21) , 10879-10893). To access the required 2oxoindolylacetonitrile derivatives III (Figure 27 ), we decided to explore a new route based on the application in synthesis of the reagent 4,5-dichloro-1,2,3-dithiazolium chloride (Appel salt) 1. The (Figure 27 ), we decided to explore a new route based on the application in synthesis of the reagent 4,5-dichloro-1,2,3-dithiazolium chloride (Appel salt) 1. The work described in this poster represents further application of Appel salt in the conception of novel heterocyclic rings to access to original bioactive compounds. Fragment libraries are commonly assembled by rule of three filtering followed by manual curation. However, the robust experimental data that ensures the proper physicochemical attributes needed for high-concentration screening is often lacking and replaced instead by in silico calculations of uncertain predictive value. A fragment collection with experimentally-determined aqueous solubility will address a major source of false positives and attrition in fragment screening libraries: aggregation, stability and solubility. 1 H NMR spectral data in aqueous buffer will further enable practitioners to rapidly build fragment pools and initiate screening.
Synthesis and Biological Activities of New 2-Mercapto-(2-Oxoindolin-3-ylidene)acetonitrile Derivatives (P36)
Boris Letribot, Régis Delatouche, Jean-René Chérouvrier, Lisianne Domon and Valérie Thiéry
Diversity selection methods in shape, scaffold, fingerprint and predicted property space combined with industry-standard substructure filtering were used to select over 2500 Key Organics compounds for experimental profiling. NMR and LC-MS analysis allowed the careful selection of highly-soluble fragments with desirable physicochemical and stability characteristics. Importantly, the curated molecules were enriched in cyclic scaffolds commonly found in drug candidates and spanned chemical space that minimally overlapped with existing commercial collections. This poster summarizes the experimental and cheminformatic features of this next generation Key Organics 'BIONET Premium Fragment Library′. Fragment libraries are commonly assembled by rule of three filtering followed by manual curation. However, the robust experimental data that ensures the proper physicochemical attributes needed for high-concentration screening is often lacking and replaced instead by in silico calculations of uncertain predictive value. A fragment collection with experimentally-determined aqueous solubility will address a major source of false positives and attrition in fragment screening libraries: aggregation, stability and solubility. 1 H NMR spectral data in aqueous buffer will further enable practitioners to rapidly build fragment pools and initiate screening.
Diversity selection methods in shape, scaffold, fingerprint and predicted property space combined with industry-standard substructure filtering were used to select over 2500 Key Organics compounds for experimental profiling. NMR and LC-MS analysis allowed the careful selection of highly-soluble fragments with desirable physicochemical and stability characteristics. Importantly, the curated molecules were enriched in cyclic scaffolds commonly found in drug candidates and spanned chemical space that minimally overlapped with existing commercial collections. This poster summarizes the experimental and cheminformatic features of this next generation Key Organics 'BIONET Premium work described in this poster represents further application of Appel salt in the conception of novel heterocyclic rings to access to original bioactive compounds. Fragment libraries are commonly assembled by rule of three filtering followed by manual curation. However, the robust experimental data that ensures the proper physicochemical attributes needed for high-concentration screening is often lacking and replaced instead by in silico calculations of uncertain predictive value. A fragment collection with experimentally-determined aqueous solubility will address a major source of false positives and attrition in fragment screening libraries: aggregation, stability and solubility. 1 H NMR spectral data in aqueous buffer will further enable practitioners to rapidly build fragment pools and initiate screening.
Diversity selection methods in shape, scaffold, fingerprint and predicted property space combined with industry-standard substructure filtering were used to select over 2500 Key Organics compounds for experimental profiling. NMR and LC-MS analysis allowed the careful selection of highly-soluble fragments with desirable physicochemical and stability characteristics. Importantly, the curated molecules were enriched in cyclic scaffolds commonly found in drug candidates and spanned chemical space that minimally overlapped with existing commercial collections. This poster summarizes the experimental and cheminformatic features of this next generation Key Organics 'BIONET Premium Fragment Library′. Twenty different compounds were identified through in silico screening as potential lead compounds targeting DEAD-box protein 1 (DED1) of c-FLIP. HeLa cells were treated with these compounds in combination with TRAIL to test for their ability to sensitise HeLa cells to TRAILmediated apoptosis. Caspase-mediated apoptosis was confirmed through rescue with a pan-caspase inhibitor. Three of twenty compounds in combination with TRAIL successfully induced apoptosis in HeLa cells rescuable by caspase inhibitor. Further work is in progress to confirm c-FLIP inhibitor activity of these compounds through co-immunoprecipitation while analogues of the best performing lead compound are synthesised.
University of Nottingham Managed Chemical Compound Collection (MCCC) (P41)
Lubna Hashmi, Peter Fischer and Michael Stocks
Centre for Biomolecular Sciences, University of Nottingham, Nottingham, Nottinghamshire NG7 2RD, United Kingdom; e-mail: michael.stocks@nottingham.ac.uk Twenty different compounds were identified through in silico screening as potential lead compounds targeting DEAD-box protein 1 (DED1) of c-FLIP. HeLa cells were treated with these compounds in combination with TRAIL to test for their ability to sensitise HeLa cells to TRAIL-mediated apoptosis. Caspase-mediated apoptosis was confirmed through rescue with a pan-caspase inhibitor. Three of twenty compounds in combination with TRAIL successfully induced apoptosis in HeLa cells rescuable by caspase inhibitor. Further work is in progress to confirm c-FLIP inhibitor activity of these compounds through co-immunoprecipitation while analogues of the best performing lead compound are synthesised. Compound library for high and medium throughput screening; • >85K Structurally diverse drug-like molecules;
An Affordable and Automated Compound Management Facility
Molecules obey Lipinski "rule of 5"; No reactive functional groups.
Purity Analysis and Structural Confirmation
• Samples stored at optimum condition as 10mM DMSO stock solutions;
• Dedicated LC-MS system to ensure purity of compounds.
Medicinal and Computation Chemistry Support
• Collaborative projects welcome.
For further information please contact:
Dr Michael Stocks; Head of Division of Medicinal Chemistry and Structural Biology; michael.stocks@nottingham.ac.uk
Conclusions
The meeting attracted 114 delegates with successful growth of both the network membership and the geographical range of attendee home countries, including France, Germany, Russia, Spain, Portugal, Ireland, Italy and the United Kingdom. The programme comprised a discipline-leading line-up of presenters from both academic and industrial sectors (including talks from 2 plenaries, 12 keynotes and 6 young researchers, and 41 posters), spanning a broad range of topics related to medicinal chemistry. For the first time, the inclusion of a pre-conference workshop expanded attendee knowledge and skills in the area of quantitative pharmacology. In addition, attendees of the conference dinner enjoyed some words from Emeritus Prof. Malcolm Stevens FRS (UoN), who appropriately wore a bowtie dyed with the original mauveine made by William Henry Perkin.
A number of prizes were awarded, with the best poster prize (sponsored by the Royal Society of Chemistry) going to Mirjana Antonijevic (UNICAEN, France), the best young researcher oral presentation to Scott Grossman (School of Pharmacy, University of Nottingham) and the MDPI Pharmaceuticals travel award to Jorge Grilo (University of Lisbon).
The 28th Annual GP2A Medicinal Chemistry Conference will take place between 26 and 28 August 2020 at the University of La Rochelle, France.
The GP2A committee and the local organizing committee thank the Division of Biomolecular Science and Medicinal Chemistry, School of Pharmacy (UoN), and all the sponsors and exhibitors for supporting this annual event.
